proteas
enzym
catalyz
cleavag
protein
case
hiv
virusspecif
proteas
need
cleav
viru
coat
protein
final
activ
form
proteas
inhibitor
substanc
inhibit
action
proteas
enzym
replic
cycl
seri
step
viru
cell
goe
multipli
shingl
erupt
rash
usual
girdl
l
cingulu
henc
shingl
distribut
trunk
result
infect
varicella
zoster
viru
time
reduct
observ
quantiti
exampl
blood
concentr
drug
teratogenesi
product
fetal
abnorm
agent
therapeut
index
numer
ratio
concentr
need
achiev
desir
effect
patient
concentr
produc
unaccept
toxic
patient
thymidin
kinas
enzym
catalyz
transfer
phosphoryl
group
donor
adenosin
triphosph
sugar
deoxyribos
compon
thymidin
molecul
build
block
dna
viremia
presenc
viru
bloodstream
virion
complet
viru
includ
coat
nucleic
acid
core
antivir
agent
drug
approv
usa
food
drug
administr
fda
treatment
control
viral
infect
target
stage
viral
life
cycl
ideal
antivir
agent
effect
activ
replic
latent
virus
howev
avail
antivir
agent
effect
replic
virus
eight
member
human
herpesvirida
famili
vzv
epsteinbarr
viru
ebv
cmv
human
herp
human
herp
human
herp
hallmark
herpesvirus
abil
establish
latenc
within
neuron
ganglia
nervou
system
cell
immun
system
reactiv
period
stress
trauma
immun
suppress
chemistri
mechan
action
antivir
activ
acyclovir
guanin
synthet
acycl
purin
nucleosid
analogu
lack
hydroxyl
group
nucleosid
acyclovir
phosphoryl
activ
triphosph
metabolit
inhibit
viral
dna
synthesi
figur
viral
encod
thymidin
kinas
tk
present
herpesvirusinfect
cell
catalyz
phophoryl
acyclovir
monophosph
host
cell
tk
kinas
phosphoryl
acyclovir
monophosph
metabolit
effici
acyclovir
highli
select
cell
engag
activ
viral
replic
affect
noninfect
cell
monophosph
subsequ
phosphoryl
di
triphosph
cellular
kinas
result
acyclovir
triphosph
concentr
much
higher
hsvinfect
uninfect
cell
acyclovir
triphosph
inhibit
viral
dna
synthesi
compet
deoxyguanosin
triphosph
dgtp
substrat
viral
dna
polymeras
illustr
figur
sinc
acyclovir
triphosph
lack
hydroxyl
group
requir
dna
chain
elong
grow
chain
dna
termin
addit
incorpor
acyclovir
trap
viral
dna
polymeras
prevent
initi
viral
dna
replic
viral
polymeras
greater
affin
acyclovir
triphosph
cellular
dna
polymeras
result
littl
incorpor
acyclovir
cellular
dna
vitro
acyclovir
activ
averag
ec
mg
ml
mg
ml
vzv
mg
ml
varicella
viru
much
less
suscept
acyclovir
hsv
henc
higher
dose
acyclovir
requir
treatment
vzv
infect
ebv
tk
poor
effici
util
acyclovir
substrat
therefor
higher
acyclovir
concentr
requir
ebv
inhibit
cmv
lack
virusspecif
tk
rel
resist
bioavail
oral
formul
acyclovir
peak
concentr
approxim
mg
ml
attain
multidos
oral
administr
mg
acyclovir
respect
higher
plasma
acyclovir
level
achiev
intraven
administr
plasma
halflif
h
older
children
adult
normal
renal
function
h
neonat
normal
creatinin
clearanc
elimin
acyclovir
prolong
individu
renal
dysfunct
halflif
approxim
h
person
endstag
renal
diseas
acyclovir
minim
metabol
approxim
excret
unchang
urin
via
renal
tubular
secret
glomerular
filtrat
initi
recurr
episod
genit
hsv
infect
treat
acyclovir
recurr
episod
suppress
acyclovir
topic
acyclovir
effect
treatment
genit
hsv
intraven
acyclovir
mg
kg
day
three
divid
dose
day
effect
treatment
first
episod
genit
herp
result
signific
reduct
median
durat
viral
shed
pain
time
complet
heal
vs
day
reserv
patient
system
complic
oral
therapi
mg
five
time
daili
standard
treatment
recurr
genit
herp
less
sever
resolv
rapidli
primari
infect
oral
administ
acyclovir
mg
five
time
daili
mg
three
time
daili
day
shorten
durat
sign
symptom
viru
shed
time
heal
day
respect
initi
within
h
onset
symptom
oral
acyclovir
administr
effect
suppress
recurr
genit
herp
daili
administr
acyclovir
reduc
frequenc
recurr
patient
recurr
take
drug
topic
therapi
mouth
lip
infect
clinic
benefit
oral
administ
acyclovir
mg
five
time
daili
day
reduc
time
loss
crust
approxim
day
vs
day
alter
durat
pain
time
complet
heal
immunocompromis
individu
infect
hiv
transplant
recipi
afflict
frequent
sever
hsv
infect
clinic
benefit
intraven
oral
acyclovir
therapi
document
evidenc
significantli
shorter
durat
viral
shed
acceler
lesion
heal
oral
acyclovir
therapi
high
dose
immunocompromis
patient
herp
zoster
effect
valacyclovir
superior
herp
simplex
enceph
hsv
infect
brain
common
caus
sporad
fatal
enceph
unit
state
predominantli
caus
agent
herp
simplex
enceph
hse
whitley
kimberlin
acyclovir
dose
mg
kg
everi
h
mg
kg
day
day
therapi
choic
reduc
mortal
furthermor
acyclovir
recipi
return
normal
neurolog
function
neonat
hsv
infect
hsv
infect
neonat
rare
estim
case
diagnos
annual
unit
state
birth
cohort
million
kimberlin
et
al
hsv
infect
neonat
classifi
skin
eye
mouth
sem
diseas
central
nervou
system
cn
diseas
dissemin
evid
viscer
involv
hsv
diseas
classif
system
predict
sever
outcom
diseas
kimberlin
et
al
whitley
et
al
recommend
treatment
neonat
herp
infect
mg
kg
everi
h
parenter
acyclovir
durat
dictat
extent
diseas
day
sem
diseas
day
cn
dissemin
diseas
oral
acyclovir
suppress
therapi
month
recommend
parenter
acyclovir
treatment
kimberlin
et
al
babi
sem
diseas
acyclovir
recipi
develop
normal
year
infect
babi
surviv
enceph
dissemin
diseas
acyclovir
recipi
respect
develop
normal
varicella
chickenpox
common
highli
contagi
ill
caus
vzv
primarili
diseas
earli
childhood
case
occur
children
year
age
chickenpox
gener
selflimit
young
children
manifest
fever
mild
constitut
symptom
itchi
vesicular
rash
arvin
diseas
sever
neonat
adult
immunocompromis
individu
oral
acyclovir
therapi
initi
within
h
onset
rash
reduc
durat
fever
number
maximum
lesion
immunocompet
children
present
clinic
import
acyclovir
treatment
otherwis
healthi
children
chicken
pox
selflimit
result
complic
remain
uncertain
furthermor
wide
use
varicella
vaccin
protect
vzv
make
use
acyclovir
immunocompet
children
chickenpox
obsolet
acyclovir
therapi
chicken
pox
immunocompromis
host
substanti
reduc
morbid
mortal
intraven
acyclovir
treatment
mg
bodi
surfac
area
mg
kg
everi
h
day
improv
outcom
evidenc
reduct
vzv
pneumon
oral
acyclovir
therapi
indic
immunocompromis
host
chicken
pox
bioavail
valacyclovir
make
attract
altern
herp
zoster
singl
caus
reactiv
vzv
resid
latent
state
sensori
ganglia
follow
primari
varicella
chicken
pox
infect
dworkin
et
al
acut
herp
zoster
pain
debilit
condit
especi
older
adult
risk
zosterassoci
pain
persist
heal
rash
correl
increas
age
intraven
acyclovir
therapi
herp
zoster
normal
host
produc
acceler
heal
rash
resolut
pain
acut
neuriti
zosterassoci
pain
oral
acyclovir
mg
five
time
day
administr
result
acceler
heal
rash
reduct
sever
acut
neuriti
oral
acyclovir
treatment
zoster
ophthalmicu
reduc
incid
seriou
ocular
complic
kerat
uveiti
intraven
acyclovir
therapi
significantli
reduc
frequenc
cutan
dissemin
viscer
complic
herp
zoster
immunocompromis
adult
acyclovir
standard
therapi
dose
mg
kg
bodi
weight
mg
bodi
surfac
area
everi
h
day
common
mechan
confer
acyclovir
resist
mutat
hsv
genom
result
defici
alter
viral
tk
activ
occasion
hsv
strain
tk
alter
maintain
abil
phosphoryl
natur
substrat
thymidin
select
lose
abil
phosphoryl
acyclovir
mutat
viral
dna
polymeras
gene
result
failur
incorpor
acyclovir
triphosph
progeni
dna
molecul
altern
infrequ
mechan
may
result
hsv
resist
acyclovir
resist
acyclovir
uncommon
preval
immunocompet
immunocompromis
patient
respect
englund
et
al
morfin
thouvenot
acyclovirresist
isol
vzv
identifi
much
less
frequent
acyclovirresist
hsv
recov
marrow
transplant
recipi
aid
patient
lyall
et
al
acyclovirresist
vzv
isol
alter
absent
viral
tk
function
remain
suscept
vidarabin
foscarnet
requir
viral
tk
activ
acyclovir
therapi
associ
advers
effect
common
complaint
associ
acyclovir
therapi
includ
nausea
diarrhea
headach
rapid
infus
intraven
acyclovir
result
revers
crystallin
nephropathi
report
link
intraven
acyclovir
use
cn
disturb
includ
agit
hallucin
disorient
tremor
myoclonu
cohen
et
al
wade
meyer
data
outcom
pregnant
mother
expos
acyclovir
pregnanc
show
rate
birth
defect
exceed
expect
gener
popul
pattern
defect
differ
untreat
women
chemistri
mechan
action
antivir
activ
valacyclovir
prodrug
acyclovir
lvalyl
ester
acyclovir
valacyclovir
rapidli
metabol
acyclovir
valin
enzym
valacyclovir
hydrolas
esteras
found
brush
border
gastrointestin
tract
liver
valacyclovir
provid
high
bioavail
acyclovir
threefold
fivefold
higher
obtain
oral
acyclovir
equival
plasma
level
achiev
dose
intraven
acyclovir
mechan
action
antivir
activ
spectrum
valacyclovir
similar
describ
acyclovir
antivir
spectrum
valacyclovir
encompass
vzv
cmv
effect
treatment
infect
immunocompet
individu
initi
episod
genit
herp
g
twice
daili
day
episod
therapi
recurr
herp
labiali
g
twice
day
day
recurr
genit
herp
g
mg
twice
day
day
suppress
recurr
genit
herp
g
mg
day
immunocompromis
patient
valacyclovir
effect
episod
therapi
g
twice
day
day
suppress
recurr
genit
herp
mg
twice
day
g
day
valacyclovir
g
three
time
daili
day
superior
acyclovir
reduct
pain
associ
shingl
mechan
resist
valacyclovir
similar
acyclovir
valacyclovir
similar
side
effect
profil
acyclovir
howev
crystallin
nephropathi
report
use
chemistri
mechan
action
antivir
activ
cidofovir
cytosin
hpmpc
acycl
phosphon
nucleotid
analogu
deoxycytidin
monophosph
cidofovir
singl
phosphat
group
attach
therefor
requir
viral
enzym
convers
monophosph
cellular
kinas
sequenti
phosphoryl
monophosph
activ
triphosph
metabolit
triphosph
metabolit
serv
competit
inhibitor
dna
polymeras
activ
form
drug
exhibit
greater
affin
viral
dna
polymeras
compar
cellular
dna
polymeras
therebi
select
inhibit
viral
replic
owe
uniqu
phosphoryl
requir
activ
cidofovir
usual
maintain
activ
acyclovirand
foscarnetresist
hsv
isol
well
ganciclovirand
foscarnetresist
cmv
mutant
cidofovir
less
potent
acyclovir
vitro
howev
cidofovir
persist
cell
prolong
period
increas
drug
activ
addit
cidofovir
produc
activ
metabolit
long
halfliv
h
permit
weekli
dose
cidofovir
vitro
activ
vzv
ebv
hpv
polyomavirus
orthopoxvirus
adenoviru
unfortun
cidofovir
concentr
kidney
cell
time
greater
tissu
produc
sever
proxim
convolut
tubul
nephrotox
administ
system
cidofovir
limit
variabl
oral
bioavail
therefor
administ
intraven
cidofovir
licens
treatment
cmv
retin
use
treat
acyclovirresist
hsv
infect
dose
regimen
mg
kg
per
week
first
week
mg
kg
everi
week
suffici
hydrat
coadministr
oral
probenecid
prevent
nephrotox
anecdot
report
divid
mg
kg
weekli
dose
three
dose
given
altern
day
week
may
reduc
renal
toxic
substanti
develop
resist
clinic
use
uncommon
howev
mutat
cmv
dna
polymeras
mediat
alter
suscept
nephrotox
princip
advers
event
associ
system
administr
cidofovir
occur
recipi
report
side
effect
includ
neutropenia
fever
diarrhea
nausea
headach
rash
anterior
uveiti
ocular
hypotonia
chemistri
mechan
action
antivir
activ
foscarnet
inorgan
pyrophosph
analogu
phosphonoacet
acid
inhibit
hhv
includ
ganciclovirresist
cmv
isol
acyclovirresist
hsv
vzv
strain
inhibit
dna
polymeras
block
pyrophosphatebind
site
prevent
cleavag
pyrophosph
deoxynucleotid
triphosph
unlik
acyclovir
requir
activ
virusspecif
tk
foscarnet
act
directli
viru
dna
polymeras
thu
tkdefici
acyclovirresist
herpesvirus
remain
sensit
foscarnet
oral
bioavail
foscarnet
cerebrospin
fluid
csf
concentr
foscarnet
approxim
twothird
plasma
level
renal
excret
primari
rout
clearanc
foscarnet
dose
appear
urin
bone
sequestr
also
occur
result
complex
plasma
elimin
princip
indic
cmv
retin
aid
patient
mucocutan
acyclovirresist
viral
tkdefici
penciclovirresist
hsv
vzv
infect
immunocompromis
patient
mucocutan
hsv
infect
caus
vzv
immunocompromis
host
treat
foscarnet
dosag
lower
manag
cmv
retin
isol
hsv
cmv
vzv
resist
foscarnet
develop
laboratori
clinic
set
safrin
et
al
wagstaff
bryson
isol
dna
polymeras
mutant
foscarnet
toxic
includ
mainli
nephrotox
acut
tubular
necrosi
interstiti
nephriti
metabol
hematolog
abnorm
cn
side
effect
deray
et
al
macgregor
et
al
patient
may
develop
isol
combin
hypomagnesemia
hypocalcemia
hypokalemia
hypophosphatemia
cn
side
effect
includ
headach
seizur
irrit
tremor
hallucin
report
side
effect
includ
fever
rash
pain
genit
ulcer
diarrhea
nausea
vomit
chemistri
mechan
action
antivir
activ
ganciclovir
guanin
nucleosid
analogu
differ
acyclovir
hydroxymethyl
group
posit
acycl
side
chain
time
greater
vitro
activ
cmv
activ
acyclovir
almost
activ
vzv
like
acyclovir
first
step
phosphoryl
ganciclovir
monophosph
herpesvirusinfect
cell
depend
virusencod
enzym
cell
infect
tk
catalyz
phosphoryl
ganciclovir
ganciclovir
monophosph
cmv
lack
gene
tk
enzym
catalyz
initi
phosphoryl
ganciclovir
cmvinfect
cell
phosphotransferas
encod
gene
final
phosphoryl
step
diand
triphosph
cellular
kinas
ganciclovir
triphosph
serv
competit
inhibitor
herp
viral
dna
polymeras
inhibit
incorpor
guanosin
triphosph
viral
dna
incorpor
ganciclovir
triphosph
grow
viral
chain
result
slow
subsequ
cessat
dna
chain
elong
intracellular
ganciclovir
triphosph
concentr
least
tenfold
higher
cmvinfect
cell
uninfect
cell
oral
bioavail
ganciclovir
poor
concentr
ganciclovir
biolog
fluid
includ
aqueou
humor
csf
less
plasma
level
plasma
elimin
halflif
h
individu
normal
renal
function
kidney
major
rout
clearanc
ganciclovir
therefor
impair
renal
function
requir
adjust
dosag
pharmacokinet
ganciclovir
neonat
similar
adult
valganciclovir
lvalin
ester
ganciclovir
serv
oral
prodrug
ganciclovir
valganciclovir
oral
bioavail
approxim
rapidli
convert
ganciclovir
absorpt
mechan
action
spectrum
activ
similar
ganciclovir
oral
valganciclovir
given
dose
result
serum
level
approxim
ganciclovir
serum
level
achiev
intraven
ganciclovir
oral
valganciclovir
conveni
use
may
replac
intraven
ganciclovir
initi
mainten
treatment
ganciclovir
approv
treatment
chronic
suppress
cmv
retin
aid
immunocompromis
patient
prophylaxi
preemptiv
treatment
cmv
infect
highrisk
transplant
recipi
also
effect
cmv
syndrom
includ
cmv
pneumonia
cmv
coliti
gastrointestin
infect
aid
transplant
patient
immunocompromis
patient
therapi
ganciclovir
requir
induct
mainten
phase
induct
dose
mg
kg
day
two
divid
dose
given
day
mainten
dose
mg
kg
day
given
daili
day
per
week
oral
valganciclovir
dosag
mg
twice
day
mg
day
induct
mainten
therapi
respect
balfour
ganciclovir
recommend
treatment
neonat
congenit
infect
cmv
phase
iii
random
control
trial
ganciclovir
therapi
mg
kg
per
dose
administ
twice
day
week
protect
infant
hear
deterior
beyond
one
year
life
reduc
incid
neurodevelopment
delay
kimberlin
et
al
oliv
et
al
oral
valganciclovir
may
becom
avail
treatment
congenit
cmv
diseas
near
futur
random
trial
valganciclovir
treatment
mg
kg
per
dose
everi
h
six
month
newborn
congenit
cmv
diseas
associ
improv
head
circumfer
development
mileston
decreas
risk
hear
loss
progress
hear
loss
immunocompromis
patient
receiv
prolong
therapi
preval
resist
exce
two
mechan
resist
cmv
ganciclovir
alter
cmv
phosphonotransferas
code
cmv
gene
markham
fauld
reduc
intracellular
phosphoryl
ganciclovir
mutat
cmv
dna
polymeras
code
cmv
gene
resist
associ
decreas
sensit
occasion
strain
hsv
resist
acyclovir
tk
defici
also
much
less
sensit
ganciclovir
import
side
effect
ganciclovir
therapi
develop
neutropenia
thrombocytopenia
neutropenia
occur
approxim
patient
neutropenia
usual
revers
dosag
adjust
ganciclovir
withhold
treatment
thrombocytopenia
occur
patient
ganciclovir
gonad
toxic
anim
model
notabl
potent
inhibitor
spermatogenesi
caus
increas
incid
tumor
preputi
gland
male
mice
find
unknown
signific
agent
affect
dna
synthesi
ganciclovir
carcinogen
potenti
chemistri
mechan
action
antivir
activ
penciclovir
guanin
nucleosid
analogu
structur
similar
ganciclovir
differ
substitut
methylen
bridg
ether
oxygen
acycl
ribos
part
molecul
metabol
mechan
action
similar
acyclovir
except
oblig
dnachain
termin
vitro
inhibitori
effect
penciclovir
vzv
similar
acyclovir
oral
bioavail
penciclovir
poor
famciclovir
prodrug
penciclovir
improv
bioavail
approxim
diacetyl
ester
penciclovir
well
absorb
oral
administr
rapidli
metabol
penciclovir
deacetyl
gastrointestin
tract
liver
oxid
liver
posit
purin
ring
penciclovir
phosphoryl
effici
acyclovir
hsvand
vzvinfect
cell
host
cell
kinas
phosphoryl
penciclovir
acyclovir
small
compar
extent
preferenti
metabol
hsvand
vzvinfect
cell
major
determin
antivir
activ
penciclovir
triphosph
averag
tenfold
longer
intracellular
halflif
acyclovir
triphosph
vzvinfect
cell
drug
remov
penciclovir
stabl
longer
antivir
activ
allow
less
frequent
dose
compound
good
activ
vzv
penciclovir
like
acyclovir
rel
inact
cmv
ebv
penciclovir
activ
hepat
b
penciclovir
elimin
rapidli
almost
unchang
activ
tubular
secret
glomerular
filtrat
kidney
elimin
healthi
subject
approxim
h
famciclovir
avail
oral
prepar
treatment
vzv
infect
use
treatment
follow
condit
initi
episod
genit
herp
mg
three
time
day
day
episod
treatment
recurr
genit
herp
mg
twice
day
day
suppress
recurr
genit
herp
mg
twice
day
shingl
mg
everi
h
day
immunocompromis
patient
famciclovir
efficaci
episod
treatment
recurr
genit
herp
mg
twice
day
day
compar
acyclovir
famciclovir
effect
safe
well
toler
treatment
hsv
infect
hivinfect
individu
famciclovir
also
least
effect
acyclovir
ophthalm
zoster
shingl
acut
zoster
pain
immunocompromis
patient
compar
valacyclovir
famciclovir
effect
safe
conveni
treatment
zoster
penciclovir
avail
cream
topic
therapi
mucocutan
hsv
infect
particularli
recurr
herp
labiali
cold
sore
topic
penciclovir
approv
episod
therapi
herp
labiali
appli
everi
h
wake
hour
day
acceler
lesion
heal
resolut
pain
day
avail
overthecount
mani
countri
hsv
vzv
isol
resist
penciclovir
identifi
laboratori
clinic
trial
penciclovirresist
hsv
isol
immunocompet
patient
immunocompromis
patient
sariski
et
al
resist
attribut
alter
defici
tk
dna
polymeras
therapi
oral
famciclovir
well
toler
associ
headach
diarrhea
nausea
preclin
studi
famciclovir
indic
chronic
administr
tumorigen
murin
mammari
tumor
caus
testicular
toxic
rodent
chemistri
mechan
action
antivir
activ
idoxuridin
deoxyuridin
trifluorothymidin
deoxyuridin
thymidin
analogu
administ
system
nucleosid
phosphoryl
viral
cellular
kinas
activ
triphosph
deriv
inhibit
viral
cellular
dna
synthesi
parenter
administr
result
potent
antivir
activ
also
suffici
host
cytotox
prevent
system
use
drug
toxic
compound
signific
appli
topic
eye
treatment
hsv
kerat
idoxuridin
trifluorothymidin
effect
licens
treatment
hsv
kerat
topic
appli
idoxuridin
trifluorothymidin
penetr
cell
cornea
low
level
drug
detect
aqueou
humor
trifluorothymidin
efficaci
compound
treatment
choic
hsv
kerat
drop
ophthalm
solut
instil
eye
nine
time
day
idoxuridin
first
antivir
compound
receiv
fda
approv
treatment
hsv
kerat
trifluorothymidineresist
hsv
strain
alter
tk
substrat
specif
select
vitro
howev
clinic
signific
resist
establish
ophthalm
prepar
idoxuridin
trifluorothymidin
caus
local
discomfort
irrit
photophobia
edema
eyelid
less
commonli
hypersensit
reaction
well
superfici
punctat
epitheli
keratopathi
vidarabin
viraa
adenin
arabinosid
adenin
activ
hsv
vzv
cmv
vidarabin
purin
nucleosid
analogu
phosphoryl
intracellularli
mono
di
triphosph
deriv
thu
unlik
acyclovir
convers
vidarabin
activ
intracellular
deriv
requir
viral
enzym
phosphoryl
step
triphosph
deriv
competit
inhibit
dna
depend
dna
polymeras
dna
virus
approxim
time
host
cell
addit
viraa
incorpor
termin
posit
cellular
viral
dna
thu
inhibit
elong
viral
dna
synthesi
block
lower
dose
drug
host
cell
dna
synthesi
result
rel
select
antivir
effect
howev
larg
dose
viraa
cytotox
divid
host
cell
use
vidarabin
replac
acyclovir
poor
solubl
toxic
longer
avail
intraven
formul
howev
vidarabin
recogn
histor
first
antivir
agent
licens
system
treatment
although
trifluorothymidin
antivir
agent
choic
topic
treatment
hsv
kerat
patient
trifluorothymidin
use
vidarabin
suitabl
altern
topic
vidarabin
superior
idoxuridin
treatment
hsv
ocular
infect
resist
vidarabin
confer
mutat
viral
dna
polymeras
gene
degre
maxim
resist
vidarabin
fourfold
much
lower
resist
acyclovir
similar
dna
polymeras
resist
mutat
acyclovirresist
clinic
hsv
isol
alway
suscept
vitro
vidarabin
ocular
toxic
consist
occasion
hyperemia
increas
tear
low
incid
chemistri
mechan
action
antivir
activ
fomivirsen
phosphorothio
oligonucleotid
inhibit
cmv
replic
antisens
mechan
oligonucleotid
sequenc
gcg
ttt
gct
ctt
ctt
ctt
complementari
sequenc
mrna
transcript
major
immedi
earli
region
cmv
encod
sever
protein
respons
viral
gene
express
essenti
product
infecti
viral
particl
bind
fomivirsen
target
mrna
result
inhibit
protein
synthesi
subsequ
inhibit
viral
replic
vitro
fomivirsen
inhibit
cmv
replic
dosedepend
manner
mean
ic
mmol
l
pharmacokinet
assess
fomivirsen
human
intraocular
administr
limit
rabbit
model
intraocular
administr
reveal
firstord
kinet
halflif
h
fomivirsen
clear
vitreou
rabbit
cours
day
combin
tissu
distribut
metabol
system
absorpt
observ
intravitr
administr
human
fomivirsen
indic
use
hiv
patient
cmv
retin
intoler
contraind
treatment
cmv
retin
diseas
recalcitr
ganciclovir
cidofovir
treatment
activ
cidofovirand
ganciclovirresist
strain
cmv
cmv
strain
tenfold
decreas
suscept
select
vitro
howev
resist
clinic
isol
report
advers
event
fomivirsen
uveiti
includ
iriti
vitriti
occur
approxim
patient
reaction
usual
transient
revers
topic
corticosteroid
treatment
licens
antivir
agent
herp
infect
ultim
target
viral
hsv
dna
polymeras
essenti
viru
replic
recent
drug
discoveri
effort
focus
improv
efficaci
safeti
profil
current
antivir
also
explor
new
viral
target
kleymann
et
al
prodrug
cidofovir
demonstr
prodrug
approach
improv
oral
absorpt
also
reduc
toxic
parent
compound
pritelivir
helicaseprimas
inhibitor
preclin
pharmacolog
profil
outperform
current
standard
hsv
treatment
shown
promis
phase
ii
trial
vere
hodg
field
wald
et
al
weller
kuchta
recent
discoveri
antivir
activ
letermovir
terminas
inhibitor
proof
concept
herp
viru
terminas
enzym
viabl
target
new
hsv
therapi
goldner
et
al
ultim
breakthrough
treatment
herp
viru
infect
discoveri
agent
innov
strategi
elimin
herp
latenc
amantadin
rimantadin
nh
amantadin
nh
rimantadin
chemistri
mechan
action
antivir
activ
amantadin
hydrochlorid
rimantadin
hydrochlorid
symmetr
tricycl
amin
narrow
spectrum
activ
use
influenza
infect
rimantadin
fourfold
tenfold
activ
amantadin
mechan
action
drug
relat
influenza
viru
protein
integr
transmembran
protein
function
ion
channel
viru
activ
ph
drop
ph
accompani
hydrogen
flux
facilit
dissoci
protein
ribonucleoprotein
complex
ribonucleoprotein
enter
cell
nucleu
initi
replic
interf
function
protein
amantadin
rimantadin
inhibit
acidmedi
dissoci
matrix
protein
ribonuclear
protein
complex
within
endosom
event
occur
earli
viral
replic
cycl
consequ
drug
potenti
acid
phinduc
conform
chang
viral
hemagglutinin
intracellular
transport
absorpt
rimantadin
slower
compar
amantadin
amantadin
excret
unchang
urin
glomerular
filtrat
like
tubular
secret
plasma
elimin
approxim
h
individu
normal
renal
function
howev
elimin
increas
elderli
impair
creatinin
clearanc
rimantadin
extens
metabol
follow
oral
administr
elimin
h
approxim
dose
excret
unchang
urin
amantadin
rimantadin
licens
chemoprophylaxi
treatment
influenza
infect
prophylaxi
either
drug
prevent
approxim
infect
clinic
ill
caus
type
influenza
viru
lower
incid
side
effect
associ
rimantadin
use
preferenti
rimantadin
given
unimmun
member
gener
popul
wish
avoid
influenza
prophylaxi
especi
recommend
control
presum
influenza
outbreak
institut
hous
highrisk
person
highrisk
individu
includ
adult
children
chronic
disord
cardiovascular
pulmonari
system
prophylaxi
also
indic
vaccin
may
ineffect
epidem
strain
differ
substanti
vaccin
strain
influenza
week
vaccin
influenza
alreadi
activ
commun
amantadin
rimantadin
also
shown
effect
treatment
influenza
infect
adult
children
treatment
initi
within
h
onset
symptom
couch
drug
therapi
result
reduct
durat
viral
excret
fever
system
complaint
well
earlier
resumpt
normal
activ
comparison
placebo
averag
durat
ill
shorten
day
amantadin
rimantadin
given
oral
mg
day
respect
resist
amantadin
rimantadin
result
point
mutat
rna
sequenc
encod
protein
transmembran
domain
resist
typic
appear
treat
subject
within
day
initi
therapi
treat
patient
shed
resist
strain
day
treatment
clinic
signific
isol
resist
strain
treat
subject
clear
infect
ill
immunocompet
peopl
infect
drugresist
viru
similar
patient
infect
drugsensit
viru
although
spectrum
advers
event
associ
amantadin
rimantadin
qualit
similar
less
frequent
less
sever
rimantadin
amantadin
report
caus
side
effect
healthi
young
adult
take
standard
adult
dose
mg
day
side
effect
usual
mild
ceas
soon
amantadin
discontinu
although
often
disappear
continu
use
drug
cn
side
effect
occur
patient
common
includ
difficulti
think
confus
lightheaded
hallucin
anxieti
insomnia
sever
advers
effect
eg
mental
depress
psychosi
usual
associ
dose
exceed
mg
daili
patient
complain
nausea
vomit
anorexia
cn
advers
effect
associ
rimantadin
administr
significantli
less
howev
rimantadin
associ
exacerb
underli
seizur
disord
chemistri
mechan
action
antivir
activ
zanamivir
acid
oseltamivir
ethyl
ester
acid
sialic
acid
analogu
competit
inhibit
influenza
viru
neuraminidas
na
influenza
viru
na
locat
surfac
viru
respons
cleav
termin
sialic
acid
residu
essenti
releas
viru
infect
cell
viral
aggreg
spread
within
respiratori
tract
influenza
na
also
decreas
viral
inactiv
respiratori
mucou
lipophil
side
chain
zanamivir
oseltamivir
bind
influenza
viru
na
block
abil
cleav
sialic
acid
residu
zanamivir
oseltamivir
effect
influenza
influenza
b
zanamivir
poor
oral
bioavail
therefor
administ
oral
inhal
oral
inhal
dose
zanamivir
deposit
oropharynx
approxim
distribut
airway
lung
local
respiratori
mucos
concentr
zanamivir
exce
ng
ml
sputum
h
inhal
ie
concentr
requir
inhibit
influenza
b
virus
approxim
inhal
dose
absorb
system
peak
serum
concentr
rang
ng
ml
within
h
administr
mg
dose
plasma
h
system
absorb
zanamivir
excret
unchang
urin
although
serum
concentr
zanamivir
increas
decreas
creatinin
clearanc
adjust
dose
necessari
renal
insuffici
limit
amount
system
absorb
drug
oseltamivir
ethyl
ester
prodrug
follow
hydrolysi
hepat
esteras
convert
activ
compound
oseltamivir
carboxyl
approxim
oral
administ
oseltamivir
reach
system
circul
form
oseltamivir
carboxyl
oseltamivir
carboxyl
elimin
unchang
renal
excret
glomerular
filtrat
tubular
secret
elimin
oseltamivir
carboxyl
h
serum
concentr
drug
increas
presenc
declin
renal
function
dose
adjust
recommend
patient
renal
insuffici
zanamivir
oseltamivir
use
treatment
prevent
influenza
b
infect
treatment
otherwis
healthi
adult
children
zanamivir
oseltamivir
reduc
durat
symptom
day
provid
rel
reduct
odd
complic
given
within
h
onset
symptom
drug
also
significantli
diminish
viral
replic
respiratori
secret
zanamivir
avail
dri
powder
inhal
use
breathactiv
diskhal
deliveri
system
recommend
dose
zanamivir
patient
year
mg
twice
daili
day
oseltamivir
given
mg
twice
day
day
inhal
zanamivir
mg
daili
given
week
season
prophylaxi
reduc
likelihood
laboratori
confirm
influenza
without
symptom
influenza
diseas
influenza
diseas
fever
oseltamivir
administ
week
peak
influenza
season
significantli
reduc
risk
contract
influenza
protect
efficaci
oseltamivir
prevent
cultureproven
influenza
virus
resist
zanamivir
oseltamivir
gener
vitro
passag
cell
cultur
clinic
influenza
viru
isol
reduc
suscept
na
inhibitor
report
de
jong
et
al
two
mechan
resist
mutat
hemagglutin
receptorbind
site
mutat
conserv
portion
na
enzym
activ
site
gener
resist
virus
mutat
na
enzym
thought
decreas
infect
fit
therefor
less
like
transmit
na
inhibitor
gener
well
toler
advers
event
follow
administr
oseltamivir
primarili
gastrointestin
nausea
vomit
occur
patient
inhal
zanamivir
result
bronchospasm
reduc
forc
expiratori
volum
zanamivir
use
caution
individu
reactiv
airway
diseas
chronic
obstruct
pulmonari
diseas
chemistri
mechan
action
antivir
activ
ribavirin
methylamin
hydrochlorid
antivir
activ
varieti
rna
dna
virus
ribavirin
nucleosid
analogu
poorli
understood
mechan
action
probabl
virusspecif
mechan
action
howev
abil
alter
nucleotid
pool
packag
mrna
appear
import
process
viru
specif
quiet
select
infect
cell
produc
mrna
noninfect
cell
major
action
inhibit
monophosph
inosin
monophosph
dehydrogenas
enzym
essenti
dna
synthesi
inhibit
may
direct
effect
intracellular
level
gmp
nucleotid
level
may
alter
triphosph
ribavirin
inhibit
format
guanyl
cap
mrna
vaccinia
venezuelan
equin
enceph
virus
addit
triphosph
potent
inhibitor
viral
mrna
methyltransferas
vaccinia
viru
capac
viral
mrna
support
protein
synthesi
markedli
reduc
ribavirin
ribavirin
may
inhibit
influenza
rnadepend
rna
polymeras
ribavirin
administ
oral
bioavail
approxim
intraven
aerosol
administr
becom
standard
treatment
rsv
infect
children
oral
dose
mg
result
peak
plasma
concentr
mg
ml
respect
intraven
dosag
mg
result
mg
ml
plasma
concentr
respect
aerosol
administr
ribavirin
result
plasma
level
function
durat
exposur
although
respiratori
secret
contain
milligram
quantiti
drug
microgram
quantiti
mg
ml
detect
plasma
kidney
major
rout
clearanc
drug
account
approxim
hepat
metabol
also
contribut
clearanc
ribavirin
notabl
ribavirin
triphosph
concentr
erythrocyt
persist
month
longer
like
persist
ribavirin
erythrocyt
contribut
hematopoiet
toxic
respiratori
syncyti
viru
ribavirin
licens
treatment
care
select
hospit
infant
young
children
sever
lower
respiratori
tract
infect
caus
rsv
use
aerosol
ribavirin
adult
children
rsv
infect
reduc
sever
ill
viru
shed
howev
placebo
control
trial
fail
demonstr
consist
decreas
need
mechan
ventil
durat
stay
intens
care
unit
durat
hospit
among
ribavirin
recipi
use
ribavirin
treatment
rsv
infect
controversi
remain
discretionari
common
advers
event
follow
aerosol
administr
ribavirin
includ
bronchospasm
malfunct
ventil
deliveri
system
usual
dosag
aerosol
ribavirin
mg
ml
drug
instil
smallparticl
aerosol
gener
spag
administ
h
day
day
avoid
potenti
exposur
health
care
worker
ribavirin
special
contain
deliveri
system
isol
room
neg
pressur
use
system
ribavirin
demonstr
efficaci
manag
lifethreaten
infect
caus
lassa
fever
hemorrhag
fever
renal
syndrom
oral
ribavirin
recommend
prophylaxi
lassa
fever
expos
contact
treatment
failur
ribavirin
occur
patient
howev
resist
ribavirin
identifi
clinic
problem
advers
effect
attribut
aerosol
therapi
ribavirin
infant
rsv
includ
bronchospasm
pneumothorax
ventil
patient
apnea
cardiac
arrest
hypotens
concomit
digitali
toxic
pulmonari
function
test
chang
ribavirin
therapi
adult
chronic
obstruct
pulmonari
diseas
note
reticulocytosi
rash
conjunct
associ
use
ribavirin
aerosol
given
oral
intraven
transient
elev
serum
bilirubin
occurr
mild
anemia
report
ribavirin
found
teratogen
mutagen
preclin
test
use
contraind
women
may
becom
pregnant
exposur
drug
concern
express
risk
person
room
infant
treat
ribavirin
aerosol
particularli
femal
childbear
age
although
risk
seem
minim
limit
exposur
awar
caution
warrant
therefor
establish
stringent
precaut
administr
ribavirin
influenza
pandem
long
pose
threat
humankind
threat
realiz
vari
extent
particular
concern
mount
late
due
continu
sporad
human
case
avian
influenza
southeast
asia
eastern
europ
africa
amantadin
rimantadin
recommend
season
avian
influenza
circul
influenza
virus
well
strain
affect
human
southeast
asia
resist
medic
zanamivir
oseltamivir
avail
option
expand
antivir
drug
arsen
influenza
research
test
number
investig
agent
includ
peramivir
although
peramivir
na
inhibitor
administ
intramuscularli
preclin
studi
mice
ferret
reveal
drug
could
protect
anim
expos
pathogen
influenza
viru
compar
untreat
anim
pyrazin
deriv
viral
rna
polymeras
inhibitor
preclin
test
stage
outbreak
novel
coronaviru
infect
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
drosten
et
al
middl
east
respiratori
syndrom
coronaviru
merscov
gueri
et
al
underscor
need
novel
antivir
drug
control
futur
outbreak
coronaviru
respiratori
virus
infect
interferon
chemistri
mechan
action
antivir
activ
ifn
glycoprotein
cytokin
intercellular
messeng
complex
array
immunomodul
antineoplast
antivir
properti
ifn
current
classifi
b
g
natur
sourc
gener
leukocyt
fibroblast
lymphocyt
respect
type
ifn
produc
recombin
dna
technolog
bind
ifn
intact
cell
membran
first
step
establish
antivir
effect
ifn
bind
cellular
receptor
activ
secondari
messeng
initi
product
multipl
protein
pivot
defens
cell
virus
mechan
action
rather
complex
thoma
et
al
antivir
effect
ifn
includ
degrad
viral
mrna
inhibit
viral
protein
synthesi
prevent
viral
infect
cell
immunomodul
effect
ifn
includ
enhanc
antigen
present
hla
ii
immun
system
activ
natur
killer
nk
cell
immun
cell
increas
cytokin
product
ifn
activ
wide
spectrum
virus
rna
virus
sensit
dna
virus
ifn
oral
bioavail
administ
intramuscularli
subcutan
includ
lesion
appear
variabl
absorpt
three
class
ifn
importantli
result
plasma
level
absorpt
ifna
complet
intramuscular
subcutan
inject
plasma
level
dose
depend
peak
h
administr
return
baselin
h
howev
antivir
activ
peak
h
slowli
decreas
baselin
day
ifn
elimin
inactiv
variou
bodi
fluid
metabol
number
organ
neglig
amount
excret
urin
unchang
ifna
molecul
coval
bond
polyethylen
glycol
peg
improv
pharmacokinet
profil
ifn
markedli
pegyl
form
ifna
pegifna
offer
conveni
weekli
instead
daili
administr
licens
treatment
hepat
b
c
major
goal
therapi
hepat
b
prevent
progress
diseas
cirrhosi
end
stage
liver
diseas
hepatocellular
carcinoma
chiaramont
et
al
yang
et
al
three
gener
accept
indic
treatment
posit
test
hbv
dna
posit
hepat
b
e
antigen
hbeag
alanin
aminotransferas
alt
level
greater
two
time
normal
treatment
end
point
differ
hbeag
posit
hbeag
neg
diseas
howev
suppress
hbv
replic
level
less
copi
per
ml
iu
ml
regard
surrog
treatment
success
result
improv
serum
alt
hepat
necroinflammatori
diseas
hepat
b
dna
polymeras
level
marker
replic
reduc
standard
ifn
therapi
clearanc
serum
hbeag
hbv
dna
polymeras
occur
treatment
use
pegyl
form
ifn
becom
common
conveni
weekli
dose
genotyp
baselin
factor
affect
respons
hbeagposit
chronic
hepat
b
patient
genotyp
b
better
respons
comparison
genotyp
c
patient
aim
therapi
chronic
hcv
infect
decreas
ultim
prevent
progress
liver
damag
lead
cirrhosi
liver
failur
hepatocellular
carcinoma
therapi
chronic
hcv
infect
indic
patient
detect
hcv
rna
viral
load
persist
elev
alt
find
cirrhosi
fibrosi
even
moder
inflamm
liver
biopsi
support
choic
therapeut
intervent
howev
biopsi
mandatori
prior
treatment
initi
standard
ifn
either
monotherapi
combin
ribavirin
use
extens
hcv
infect
combin
therapi
week
result
sustain
respons
patient
standard
treatment
hcv
infect
either
given
alon
combin
ribavirin
directact
antivir
agent
daa
genotyp
infect
associ
lower
sustain
virolog
respons
hcv
genotyp
resist
administ
ifn
document
although
neutral
antibodi
recombin
ifn
report
clinic
import
latter
observ
unknown
side
effect
frequent
ifn
standard
pegyl
administr
usual
dose
limit
influenzalik
symptom
ie
fever
chill
headach
malais
commonli
occur
symptom
usual
becom
less
sever
repeat
treatment
leukopenia
common
hematolog
abnorm
occur
treat
patient
leukopenia
usual
modest
clinic
relev
revers
upon
discontinu
therapi
increas
alt
level
may
also
occur
well
nausea
vomit
diarrhea
higher
dose
ifn
neurotox
encount
manifest
person
chang
confus
attent
deficit
disorient
paranoid
ideat
chemistri
mechan
action
antivir
activ
lamivudin
enantiom
cytidin
analogu
sulfur
substitut
carbon
atom
furanos
ring
dideoxi
thiacytidin
signific
activ
vitro
well
hbv
lamivudin
phosphoryl
triphosph
metabolit
cellular
kinas
triphosph
deriv
competit
inhibitor
viral
revers
transcriptas
chang
et
al
oral
bioavail
adult
dose
mg
kg
peak
serum
concentr
mg
ml
achiev
h
plasma
approxim
h
lamivudin
elimin
kidney
unchang
glomerular
filtrat
tubular
excret
dosag
adapt
creatinin
clearanc
lamivudin
effect
monotherapi
treatment
chronic
hbv
infect
dienstag
et
al
combin
antiretrovir
drug
treatment
hiv
infect
first
line
drug
treatment
hbeag
antihb
posit
diseas
elev
serum
alt
level
shown
predict
higher
likelihood
hbeag
loss
patient
chronic
hepat
b
treat
lamivudin
lamivudin
administ
oral
mg
day
treatment
hbv
infect
though
ideal
dose
could
higher
resist
lamivudin
monotherapi
develop
within
month
therapi
incid
lamivudin
resist
per
year
patient
becom
resist
year
treatment
lok
et
al
pawlotski
curiou
know
lamivudin
higher
dose
affect
incid
resist
lamivudin
resist
hbv
confer
hbv
strain
mutat
viral
polymeras
within
catalyt
domain
c
domain
includ
ymdd
motif
eg
within
b
domain
eg
da
et
al
mutant
reduc
replic
capac
compar
wild
type
hbv
viru
lamivudin
resist
manag
sequenti
treatment
either
adefovir
entecavir
howev
advantag
sequenti
treatment
compar
de
novo
combin
therapi
question
lamivudin
extrem
favor
toxic
profil
may
partli
lamivudin
affect
mitochondri
dna
synthesi
poor
inhibit
human
dna
polymeras
chang
et
al
highest
dose
mg
kg
day
neutropenia
encount
low
frequenc
chemistri
mechan
action
antivir
activ
adefovir
dipivoxil
bi
pivaloyloxymethyl
ester
adenin
oral
bioavail
prodrug
adefovir
phosphon
acycl
nucleotid
analogu
adenosin
monophosph
adefovir
monophosphoryl
depend
initi
phosphoryl
viral
nucleosid
kinas
exert
antivir
effect
phosphoryl
diand
triphosph
metabolit
cellular
kinas
merta
et
al
triphosph
compet
endogen
deoxyadenosin
triphosph
datp
incorpor
nascent
viral
dna
result
prematur
termin
viral
dna
synthesi
due
lack
hydroxyl
group
de
clercq
activ
hiv
hepadnavirus
herpesvirus
bioavail
adefovir
dipivoxil
human
long
intracellular
halflif
h
allow
oncedaili
dose
clearanc
adefovir
renal
excret
pharmacokinet
substanti
alter
subject
moder
sever
renal
impair
efficaci
adefovir
assess
patient
hbeag
posit
neg
diseas
set
spectrum
chronic
hepat
b
infect
recommend
dose
mg
day
adefovir
result
signific
improv
compar
placebo
marcellin
et
al
improv
liver
histolog
vs
reduct
hbv
dna
vs
log
copi
ml
normal
alt
vs
hbeag
seroconvers
vs
also
use
treatment
lamivudineresist
hbv
infect
schiff
et
al
zoulim
et
al
adefovir
resist
occur
approxim
patient
year
adefovir
monotherapi
hadziyanni
et
al
mutat
hbv
polymeras
b
domain
domain
confer
resist
adefovir
lacomb
et
al
osiowi
et
al
nephrotox
major
side
effect
higher
dose
adefovir
hadziyanni
et
al
schiff
et
al
caus
proxim
convolut
tubul
lesion
character
rise
urea
creatinin
doserel
clinic
advers
event
gastrointestin
event
includ
nausea
anorexia
diarrhea
usual
mild
intermitt
selflimit
without
need
concomit
medic
dose
interrupt
entecavir
chemistri
mechan
action
antivir
activ
entecavir
hydroxymethyl
monhydr
guanosin
nucleosid
analogu
entecavir
effici
phosphoryl
cellular
kinas
activ
triphosph
metabolit
affect
threestep
replic
hbv
prevent
prime
hbv
revers
transcriptas
prevent
revers
transcrib
hbv
pregenom
mrna
inhibit
dnadepend
dna
synthesi
ie
termin
viral
dna
synthesi
seifer
et
al
zoulim
hbv
polymeras
bind
preferenti
entecavir
triphosph
entecavir
triphosph
affect
human
mitochondri
dna
synthesi
effect
entecavir
human
cellular
polymeras
minim
studi
prior
approv
entecavir
hbv
treatment
suggest
entecavir
antihiv
activ
clinic
relev
concentr
howev
recent
studi
suggest
antihiv
activ
entecavir
drug
concentr
low
nanomolar
rang
mcmahon
et
al
sasadeusz
entecavir
well
absorb
oral
administr
achiev
peak
plasma
concentr
h
entecavir
substrat
cytochrom
cyp
enzym
system
elimin
primarili
urin
glomerular
filtrat
tubular
secret
mean
elimin
entecavir
vari
h
patient
normal
function
intracellular
halflif
triphosph
metabolit
vitro
studi
h
yamanaka
et
al
entecavir
approv
march
manag
adult
patient
chronic
hbv
infect
activ
viral
replic
andor
elev
liver
transaminas
sign
activ
diseas
histolog
examin
phase
iii
trial
respons
achiev
entecavir
surpass
previous
publish
respons
rate
lamivudin
adefovir
dipivoxil
recent
report
antihiv
activ
entecavir
entecavir
monotherapi
probabl
use
individu
hivhbv
coinfect
need
hbv
hiv
treatment
preval
rate
resist
entecavir
hbvtreatment
naiv
howev
virolog
rebound
resist
report
lamivudineresist
patient
year
switch
treatment
entecavir
entecavir
resist
requir
follow
amino
acid
sequenc
chang
revers
transcriptas
domain
hbv
baldick
et
al
advers
event
phase
iii
studi
mild
compris
headach
upper
respiratori
tract
infect
cough
fatigu
pharyng
abdomin
pain
gastrointestin
upset
common
laboratori
abnorm
alt
level
greater
five
time
upper
limit
normal
monitor
longterm
toxic
need
chemistri
mechan
action
antivir
activ
telbivudin
deoxythymidin
lconfigur
nucleosid
potent
specif
activ
hbv
hepadnavirus
telbivudin
competit
inhibitor
hbv
viral
revers
transcriptas
dna
polymeras
telbivudin
phosphoryl
cellular
kinas
triphosph
metabolit
compet
natur
occur
thymidin
triphosph
viral
dna
elong
incorpor
telbivudin
viral
dna
termin
viral
dna
chain
elong
kim
et
al
contrast
nucleosid
analogu
lamivudin
telbivudin
preferenti
inhibit
anticompl
secondstrand
dna
wherea
lamivudin
triphosph
preferenti
inhibit
complement
dna
synthesi
preliminari
studi
shown
potent
inhibit
hbv
replic
safe
profil
effect
mitochondri
metabol
telbivudin
triphosph
inhibit
human
cellular
polymeras
b
g
addit
telbivudin
triphosph
substrat
human
dna
polymeras
thu
induc
genotox
telbivudin
rapidli
absorb
oral
dose
peak
plasma
concentr
achiev
within
h
absolut
oral
bioavail
telbivudin
known
period
telbivudin
exhibit
appar
singlephas
declin
h
howev
presenc
second
slower
elimin
phase
observ
intens
sampl
healthi
volunt
h
postdos
second
phase
start
approxim
h
dose
long
observ
terminalphas
approxim
h
long
plasma
telbivudin
consist
long
intracellular
h
triphosph
vitro
studi
elimin
telbivudin
increas
renal
dysfunct
therefor
dosag
reduct
telbivudin
recommend
individu
renal
dysfunct
telbivudin
approv
octob
fda
treatment
chronic
hbv
infect
clinic
trial
primari
end
point
therapeut
respons
composit
suppress
hbv
dna
either
loss
serum
hbeag
alt
normal
one
year
hbeagposit
patient
therapeut
respons
occur
patient
treat
telbivudin
treat
lamivudin
lai
et
al
hbeagneg
patient
respons
telbivudin
lamivudin
respect
second
year
studi
telbivudin
found
superior
lamivudin
use
two
drug
combin
effect
telbivudin
monotherapi
hbeagposit
hbeagneg
recipi
telbivudin
hbv
dna
rebound
associ
resist
mutat
lamivudineresist
hbv
strain
high
level
cross
resist
telbivudin
mutat
rt
domain
hbv
associ
telbivudin
resist
seifer
et
al
advers
effect
telbivudin
report
clinic
studi
mild
moder
common
elev
creatinin
phosphokinas
cpk
enzym
present
muscl
tissu
marker
breakdown
muscl
tissu
upper
respiratori
tract
infect
fatigu
headach
abdomin
pain
cough
lai
et
al
liaw
et
al
clevudin
approv
south
korea
philippin
respect
treatment
hepat
b
demonstr
potent
antihepat
b
activ
phase
ii
iii
clinic
trial
yoo
et
al
b
like
licens
hepat
b
treatment
countri
chemistri
mechan
action
antivir
activ
clevudin
thymidin
nucleosid
analogu
unnatur
bl
configur
potent
activ
hbv
activ
ebv
clevudin
effici
phosphoryl
cellular
kinas
clevudinetriphosph
target
cell
mechan
action
mainli
inhibit
viral
plusstrand
dna
synthesi
balakrishna
pai
et
al
chong
chu
preclin
studi
reveal
human
cellular
dna
polymeras
b
g
could
util
triphosph
clevudin
substrat
henc
lack
cytotox
ec
clevudin
hbv
inhibit
valu
rang
mmol
l
clevudin
well
absorb
oral
administr
estim
long
halflif
h
clevudin
approv
treatment
chronic
hepat
b
infect
south
korea
philippin
random
placebocontrol
phase
iii
studi
south
korea
chronic
hbeagposit
patient
receiv
mg
clevudin
daili
week
maintain
log
log
viral
suppress
week
respect
uniqu
characterist
clevudin
slow
rebound
viremia
cessat
treatment
vitro
studi
suggest
may
crossresist
lamivudineresist
hbv
mutant
mutat
associ
resist
lamivudin
adefovir
select
week
clevudin
treatment
yoo
et
al
clinic
trial
clevudin
well
toler
without
seriou
advers
event
report
howev
develop
clevudin
hold
due
associ
sever
myopathi
mitochondri
toxic
occur
sever
month
cessat
clevudin
treatment
patient
seok
et
al
chemistri
mechan
action
antivir
activ
chemistri
mechan
action
tenofovir
disoproxil
fumar
describ
section
tenofovir
disoproxil
fumar
antihiv
agent
tenofovir
signific
activ
vitro
hbv
tenofovir
approv
fda
treatment
hiv
treatment
chronic
hbv
infect
tenofovir
given
oral
mg
day
one
mg
tablet
day
treatment
hbv
infect
effect
wild
type
lamivudineresist
hbv
strain
tenofovir
potent
adefovir
dipivoxil
treatment
hbv
infect
del
poggio
et
al
tan
et
al
hivinfect
patient
treat
tenofovir
report
nephrotox
bone
miner
densiti
loss
osteomalacia
gafni
et
al
grund
et
al
lee
marosok
therefor
monitor
renal
nonren
advers
effect
tenofovir
hbv
patient
essenti
boceprevir
good
bind
k
nm
cellular
activ
nm
venkatraman
hcv
replicon
model
treatment
boceprevir
result
log
reduct
hcv
rna
h
day
respect
initi
phase
trial
combin
peginterferon
boceprevir
result
greatest
reduct
hcv
rna
addit
sarrazin
et
al
drugdrug
interact
area
curv
auc
drug
compar
auc
drug
given
alon
bioavail
anim
rang
indic
incomplet
absorpt
howev
boceprevir
display
rather
high
liverplasma
averag
ratio
rat
indic
good
uptak
target
tissu
boceprevir
metabol
primarili
aldoketo
reductas
akr
reduc
ketoamid
hydroxyl
amid
less
activ
venkatraman
addit
undergo
oxid
metabol
cyp
enzym
lesser
extent
boceprevir
approv
fda
first
directact
antivir
drug
hcv
genotyp
boceprevir
administ
combin
peginterferon
alfa
ribavirin
dose
boceprevir
mg
three
time
day
food
therapi
peginterferon
alfa
ribavirin
week
leadin
period
recommend
ad
boceprevir
base
result
clinic
trial
leadin
period
allow
peginterferon
ribavirin
reach
steadyst
concentr
avoid
period
function
monotherapi
boceprevir
reduc
develop
drug
resist
hcv
kwo
poordad
et
al
responseguid
durat
therapi
recommend
hcv
rna
level
undetect
week
patient
may
treat
tripl
therapi
boceprevir
peginterferon
ribavirin
week
hcv
rna
detect
week
undetect
week
tripl
therapi
continu
week
follow
combin
peginterferon
ribavirin
tail
total
week
therapi
kwo
vitro
resist
mutat
select
boceprevir
replicon
cell
reveal
follow
mutat
popul
sequenc
domain
isol
clinic
trial
reveal
major
mutat
minor
mutat
kwo
commonli
report
advers
effect
fatigu
anemia
nausea
headach
dysgeusia
boceprevir
use
combin
peginterferon
ribavirin
poordad
et
al
perni
et
al
telaprevir
first
bind
weakli
proteas
form
coval
bond
hydroxyl
group
catalyt
serin
ketocarbonyl
group
telaprevir
dissoci
complex
min
telaprevir
select
hcv
inhibit
serin
proteas
telaprevir
readili
absorb
oral
max
h
cmax
cmin
auc
telaprevir
higher
telaprevir
given
combin
peginterferon
ribavirin
given
monotherapi
highfat
breakfast
increas
auc
compar
standard
meal
matthew
lancast
telaprevir
metabol
liver
reduct
hydrolysi
oxid
telaprevir
substrat
inhibitor
cyp
isozym
telaprevir
substrat
inhibitor
pglycoprotein
agent
induc
cyp
pglycoprotein
may
reduc
plasma
concentr
telaprevir
telaprevir
elimin
mainli
fece
extent
expir
air
urin
telaprevir
approv
may
fda
treatment
hcv
genotyp
infect
patient
base
efficaci
toler
clinic
trial
mchutchison
et
al
zeuzem
et
al
telaprevir
administ
combin
peginterferon
ribavirin
recommend
dosag
telaprevir
mg
time
day
respondguid
durat
treatment
recommend
telaprevir
combin
therapi
recommend
durat
treatment
telaprevir
week
combin
peginterferon
ribavirin
hcv
rna
level
monitor
week
determin
combin
treatment
durat
assess
treatment
futil
recommend
patient
relaps
infect
hcv
rna
undetect
week
tripl
therapi
telaprevirpeginterferonribavirin
given
week
addit
week
dual
therapi
peginterferonribavirin
total
week
therapi
hcv
rna
detect
week
andor
tripl
therapi
telaprevirpeginterferonribavirin
given
week
addit
week
dual
therapi
peginterferonribavirin
total
week
therapi
prior
partial
null
responsd
patient
tripl
therapi
telaprevirpeginterferonribavirin
given
week
addit
week
dual
therapi
peginterferonribavirin
total
week
therapi
mutat
associ
telaprevir
resist
minor
mutat
confer
low
level
resist
major
mutat
confer
high
level
resist
clinic
trial
preval
advers
effect
commonli
associ
telaprevir
combin
peginterferonribavirin
versu
peginterferonribavirin
rash
vs
pruritu
vs
nausea
vs
diarrhea
vs
anemia
vs
hezod
et
al
mchutchison
et
al
chemistri
mechan
action
antivir
activ
simeprevir
n
cyclopropylsulfonyl
oxi
c
cyclopropa
g
carboxamid
hcv
proteas
inhibitor
directact
antivir
agent
treatment
chronic
hcv
infect
k
valu
simeprevir
hcv
proteas
genotyp
nm
respect
lin
et
al
rosenquist
et
al
simeprevir
highli
select
versu
evalu
human
proteas
vitro
combin
studi
simeprevir
interferon
ribavirin
inhibitor
result
addit
synergist
effect
simeprevir
activ
hcv
genotyp
combin
ribavirin
interferon
simeprevir
show
addit
synergist
effect
respect
lin
et
al
pk
profil
simprevir
vari
differ
anim
dog
simeprivir
achiev
bioavail
oral
administr
mg
kg
high
c
max
mm
auc
ng
h
ml
long
halflif
h
rosenquist
et
al
oral
administr
rat
simeprevir
well
distribut
high
concentr
observ
liver
liverplasma
ratio
achiev
high
drug
concentr
liver
critic
hcv
daa
given
viral
replic
hcv
occur
almost
exclus
hepatocyt
simeprevir
bind
extens
plasma
protein
howev
shift
replicon
ec
valu
observ
addit
human
serum
albumin
simeprevir
inhibit
pglycoprotein
potenti
drugdrug
interact
simeprevir
approv
novemb
fda
treatment
chronic
hcv
infect
patient
recommend
dose
simeprevir
mg
day
administ
combin
peginterferon
ribavirin
prior
relaps
patient
includ
cirrhosi
receiv
addit
week
peginterferon
alfa
ribavirin
complet
week
treatment
simeprevir
peginterferon
alfa
ribavirin
total
treatment
durat
week
prior
nonrespond
patient
includ
cirrhosi
receiv
addit
week
peginterferon
alfa
ribavirin
complet
week
treatment
simeprevir
peginterferon
alfa
ribavirin
total
treatment
durat
week
vitro
drug
resist
select
studi
reveal
mutat
posit
either
alon
combin
confer
vari
degre
resist
simeprevir
lenz
et
al
clinic
trial
patient
breakthrough
viremia
relaps
mutat
alon
combin
mutat
hcv
izumi
et
al
common
advers
effect
headach
fatigu
pyrexia
influenzalik
ill
similar
simeprevir
placebo
arm
howev
rash
photosensit
reaction
higher
simeprevir
arm
mann
et
al
nucleotid
analogu
polymeras
inhibitor
directact
antivir
agent
hepat
c
sofosbuvir
phosphoryl
host
cellular
kinas
uridin
triphosph
analogu
respons
antivir
activ
follow
oral
administr
sofosbuvir
peak
plasma
concentr
observ
h
postdos
regardless
dose
level
base
popul
pharmacokinet
analysi
subject
genotyp
hcv
infect
coadminist
ribavirin
without
pegyl
interferon
geometr
mean
steadi
state
auc
sofosbuvir
predomin
circul
metabolit
sofosbuvir
ng
h
ml
ng
h
ml
respect
sofosbuvir
approxim
bound
human
plasma
protein
bind
independ
drug
concentr
rang
mg
ml
renal
elimin
via
glomerular
filtrat
activ
tubular
secret
metabolit
median
h
rodrigueztorr
et
al
sofosbuvir
substrat
pglycoprotein
breast
cancer
resist
protein
brcp
drug
transport
sofosbovir
metabol
cytochrom
cyp
isoenzym
induc
inhibit
metabol
agent
substrat
enzym
sofosbuvir
approv
decemb
fda
treatment
chronic
hcv
infect
patient
recommend
use
combin
ribavirin
genotyp
infect
combin
peginterferon
ribavirin
genotyp
infect
recommend
dose
sofosbuvir
mg
daili
combin
ribavirin
ribavirin
peginterferon
recommend
regim
treatment
durat
patient
hcv
genotyp
sofosbuvir
given
peginterferon
ribavirin
week
genotypo
patient
sofosbuvir
combiant
ribavirin
week
genotyp
patient
sofosbuvir
combin
ribavirin
week
sofosbuvir
high
barrier
resist
vitro
drug
resist
select
studi
reveal
mutat
could
reduc
suscept
sofosbuvir
subsequ
mutat
observ
minor
patient
receiv
sofosbuvir
treatment
clinic
trial
clinic
signific
mutat
known
common
advers
effect
sofosbuvir
given
combin
peginterferon
ribavirin
fatigu
headach
nausea
insomnia
anemia
current
antivir
agent
either
inhibit
hepat
b
replic
invok
immun
respons
may
necessari
suffici
effect
viral
control
dusheiko
antonakopoulo
moreov
antivir
resist
remain
concern
longterm
therapi
search
novel
agent
treatment
strategi
minim
resist
good
longterm
safeti
profil
focu
ongo
research
cheng
et
al
emtricitabin
licens
treatment
hiv
infect
also
activ
hbv
yet
fdaapprov
indic
number
new
nucleosid
nucleotid
analogu
pipelin
elvucitabin
valtorcitabin
amdoxovir
racivir
miv
blfddc
alamifovir
hepavir
b
may
soon
part
armamentarium
hepat
b
treatment
anoth
challeng
manag
hepat
b
individu
hiv
coinfect
appropri
combin
regimen
individu
coinfect
expect
near
futur
target
treatment
hbv
alter
outcom
take
account
impact
hbv
treatment
hiv
last
decad
usher
unparallel
advanc
treatment
hcv
advent
daa
provid
highli
effect
well
toler
shorter
durat
hcv
therapi
sever
next
gener
daa
clinic
develop
soon
make
interferonbas
hcv
regimen
thing
past
afdhal
et
al
b
feld
feld
et
al
kowdley
et
al
b
poordad
et
al
futur
goal
hcv
therapi
improv
toler
shorten
durat
therapi
discoveri
agent
pan
genotyp
activ
overcom
issu
resist
avail
costeffect
regimen
hpv
small
dna
virus
strict
epitheli
tropism
hpv
infect
induc
hyperprolifer
epitheli
cell
lead
broad
spectrum
human
diseas
rang
benign
wart
selflimit
malign
neoplasm
gener
virusspecif
effect
system
therapi
avail
furthermor
treatment
diseas
current
therapi
shown
reduc
rate
transmiss
recent
fdaapprov
quadrival
prophylact
vaccin
shown
clinic
trial
effect
prevent
highgrad
vulval
vagin
lesion
associ
hpv
time
prophylact
vaccin
expect
reduc
incid
hpv
infect
particularli
infect
due
vaccin
type
ifn
antiprolif
antivir
immunomodulatori
properti
ifn
administ
mostli
ifna
topic
system
intralesion
variabl
result
effect
use
combin
either
local
surgeri
podophyllotoxin
sever
larg
control
trial
demonstr
inconsist
clinic
benefit
use
standard
ifna
therapi
condyloma
acuminatum
caus
hpv
refractori
cytodestruct
therapi
intralesion
therapi
pain
system
therapi
associ
influenzalik
symptom
fever
myalgia
furthermor
ifn
treatment
expens
limit
efficaci
immunomodul
approv
fda
topic
treatment
extern
perian
genit
wart
act
ligand
tolllik
receptor
activ
macrophag
dendrit
cell
releas
ifn
proinflammatori
cytokin
imiquimod
applic
gradual
clearanc
wart
occur
patient
averag
week
advers
effect
applic
site
reaction
irrit
pruritu
flake
eros
system
effect
includ
fatigu
influenzalik
ill
podophyllotoxin
main
cytotox
ingredi
podophyllin
resin
use
mani
year
topic
treatment
wart
exact
mechan
action
unknown
podophyllotoxin
solut
gel
similar
effect
imiquimod
may
advers
effect
advers
effect
includ
irrit
adjac
skin
local
eros
ulcer
scar
trichloroacet
acid
podophyllotoxin
cryotherapi
liquid
nitrogen
cryprob
remain
wide
use
treatment
extern
genit
wart
respons
rate
least
respond
recurr
current
therapi
target
antivir
therapi
result
physic
remov
lesion
induct
nonspecif
inflamm
therebi
induc
bystand
immun
respons
urgent
need
develop
specif
effect
antivir
agent
hpv
infect
enterovirus
includ
nearli
serotyp
close
relat
pathogen
caus
wide
spectrum
human
ill
mild
nonspecif
fever
common
upper
respiratori
infect
asept
mening
sever
myocard
enceph
paralyt
poliomyel
certain
patient
includ
antibodydefici
individu
bone
marrow
recipi
neonat
may
develop
potenti
lifethreaten
enteroviru
infect
therapeut
option
limit
case
seri
use
immun
serum
globulin
pleconaril
seriou
enterovir
infect
pleconaril
fail
secur
fda
approv
induct
cyp
enzym
activ
potenti
drug
interact
particularli
interfer
oral
contracept
pleconaril
poordad
et
al
propyl
phenyl
trifluoromethyl
exert
antivir
effect
integr
hydrophob
pocket
insid
virion
prevent
viral
replic
inhibit
viral
uncoat
block
viral
attach
host
cell
receptor
thu
interrupt
infect
cycl
viral
capsid
structur
target
pleconaril
rel
conserv
among
picornavirus
pleconaril
broad
spectrum
potent
activ
enterovirus
rhinovirus
pleconaril
bioavail
given
oral
high
level
bioavail
achiev
substitut
trifluoromethyl
oxadiazol
ring
reduc
degrad
liver
enzym
involv
oxid
process
metabol
stabil
reflect
drug
long
serum
halflif
h
oral
dose
pleconaril
also
readili
penetr
bloodbrain
barrier
phase
trial
pleconaril
treatment
common
cold
signific
reduct
rhinorrhea
day
mg
three
time
daili
reduct
sever
score
compar
placebo
subsequ
trial
confirm
modest
reduct
length
symptom
common
cold
patient
treat
pleconaril
hayden
et
al
patient
compromis
humor
immun
agammaglobulinemia
contract
enterovir
infect
may
develop
chronic
mening
meningoenceph
often
fatal
outcom
case
report
efficaci
pleconaril
patient
treatment
enterovir
mening
two
larg
studi
show
margin
statist
improv
clinic
score
pleconariltr
group
desmond
et
al
subsequ
small
studi
infant
proven
enterovir
mening
unit
state
enough
power
show
unequivoc
benefit
pleconaril
abzug
et
al
resist
pleconaril
report
serotyp
enterovirus
howev
mechan
well
understood
pleconaril
gener
well
toler
common
advers
event
headach
diarrhea
nausea
longterm
use
pleconaril
associ
increas
menstrual
irregular
women
pleconaril
licens
treatment
enterovir
infect
urgent
need
identifi
altern
drug
might
effect
sever
investig
compound
howev
none
reach
phase
clinic
trial
combin
drug
like
offer
best
chanc
cure
protect
enteroviru
infect
futur
combin
three
antihiv
agent
multidrug
regimen
often
term
highli
activ
antiretrovir
therapi
haart
effici
inhibit
hiv
viral
replic
achiev
low
undetect
circulatori
level
startoftheart
treatment
aid
hivinfect
individu
drug
combin
principl
aim
obtain
synerg
compound
reduc
likelihood
develop
drug
resist
viru
minim
toxic
avail
antihiv
drug
categor
accord
step
target
within
hiv
viral
life
cycl
figur
bind
inhibitor
exampl
coreceptor
antagonist
maraviroc
fusion
inhibitor
enfuvirtid
revers
transcriptas
inhibitor
nucleosidenucleotid
zidovudin
didanosin
zalcitabin
stavudin
lamivudin
abacavir
emtricitabin
tenofovir
nonnucleosid
nevirapin
delavirdin
efavirenz
analogu
integras
inhibitor
raltegravir
proteas
inhibitor
saquinavir
indinavir
ritonavir
nelfinavir
amprenavir
fosamprenavir
lopinavir
atazanavir
tipranavir
darunavir
fixeddos
combin
oncedaili
dosag
form
mani
antihiv
agent
avail
fixeddos
combin
zidovudinelamivudin
zidovudinelamivudineabacavir
abacavirlamivudin
tenofoviremtricitabin
tenofovir
emtricitabineefavirenz
chemistri
mechan
action
antivir
activ
maraviroc
cyclohexanecarboxamid
first
class
coreceptor
antagonist
licens
august
hiv
treatment
maraviroc
select
bind
human
chemokin
receptor
present
cell
membran
prevent
interact
necessari
enter
cell
inhibit
replic
laboratori
strain
primari
isol
vitro
mean
ec
maraviroc
variou
strain
rang
nmol
l
ng
ml
cell
cultur
maraviroc
activ
dualtrop
virus
valu
mmol
l
antivir
activ
maraviroc
evalu
absolut
bioavail
mg
dose
respect
peak
plasma
concentr
maraviroc
attain
h
follow
singl
oral
dose
mg
administ
uninfect
volunt
maraviroc
bound
approxim
human
plasma
protein
princip
metabol
cytochrom
system
metabolit
essenti
inact
maraviroc
substrat
efflux
transport
pglycoprotein
pgp
therefor
pharmacokinet
like
modul
inhibitor
induc
enzymestransport
termin
halflif
healthi
subject
h
maraviroc
approv
use
combin
antihiv
agent
treatment
adult
treatmentexperienc
evid
viral
replic
strain
resist
multipl
antiretrovir
agent
resist
profil
treatmentna
treatmentexperienc
subject
fulli
character
variant
reduc
suscept
maraviroc
select
cell
cultur
follow
serial
passag
two
virus
maraviroc
resist
virus
remain
evid
chang
viru
viru
two
amino
acid
residu
substitut
tabl
letter
code
amino
acid
region
envelop
glycoprotein
shown
necessari
maravirocresist
phenotyp
isol
isol
acid
residu
delet
loop
dqai
posit
associ
maraviroc
resist
clinic
relev
mutat
known
common
advers
event
report
maraviroc
cough
fever
upper
respiratori
tract
infect
rash
musculoskelet
symptom
abdomin
pain
dizzi
product
label
includ
warn
liver
toxic
hepatox
statement
possibl
heart
attack
tabl
threelett
onelett
code
amino
acid
residu
enfuvirtid
chemistri
mechan
action
antivir
activ
enfuvirtid
linear
acid
synthet
peptid
nterminu
acetyl
cterminu
carboxamid
first
licens
agent
class
fusion
inhibitor
enfuvirtid
interfer
entri
cell
inhibit
fusion
viral
cellular
membran
figur
enfuvirtid
bind
first
heptadrepeat
subunit
viral
envelop
glycoprotein
prevent
conform
chang
requir
fusion
viral
cellular
membran
ic
enfuvirtid
baselin
clinic
isol
rang
nmol
l
ng
ml
enfuvirtid
activ
dual
tropic
virus
activ
enfuvirtid
administ
twice
daili
subcutan
inject
singledos
vial
contain
mg
enfuvirtid
deliveri
approxim
mg
ml
reconstitut
absolut
bioavail
ae
follow
mg
bid
dose
enfuvirtid
subcutan
combin
antiretrovir
agent
infect
subject
median
max
h
rang
h
enfuvirtid
catabol
proteolyt
enzym
metabol
hepat
isoenzym
system
known
clinic
signific
interact
enfuvirtid
medic
enfuvirtid
approv
fda
march
use
adult
children
age
older
advanc
hiv
infect
enfuvirtid
use
antihiv
agent
treat
infect
patient
treatmentexperienc
detect
viral
load
even
though
take
antihiv
agent
isol
reduc
suscept
enfuvirtid
select
vitro
genotyp
analysi
resist
isol
show
mutat
result
amino
acid
substitut
enfuvirtid
bind
domain
posit
envelop
glycoprotein
clinic
trial
isol
reduc
suscept
enfuvirtid
recov
subject
fail
enfuvirtidecontain
regimen
isol
decreas
suscept
enfuvirtid
greater
fourfold
exhibit
genotyp
chang
codon
encod
domain
amino
acid
clinic
isol
resist
nucleosid
analogu
revers
transcriptas
inhibitor
nonnucleosid
analogu
revers
transcriptas
inhibitor
proteas
inhibitor
suscept
enfuvirtid
cell
cultur
common
advers
effect
enfuvirtid
inject
site
reaction
symptomat
side
effect
may
includ
insomnia
headach
dizzi
nausea
sever
case
hypersensit
describ
phase
iii
studi
bacteri
pneumonia
seen
higher
rate
patient
receiv
enfuvirtid
receiv
enfuvirtid
eosinophilia
primari
laboratori
abnorm
seen
enfuvirtid
administr
nucleosidenucleotid
revers
transcriptas
inhibitor
chemistri
mechan
action
antivir
activ
zidovudin
dideoxythymidin
pyrimidin
analogu
azido
group
substitut
hydroxyl
group
ribos
ring
zidovudin
initi
phosphoryl
cellular
tk
diphosph
cellular
thymidyl
kinas
triphosph
deriv
competit
inhibit
hiv
revers
transcriptas
function
chain
termin
zidovudin
inhibit
concentr
approxim
mg
ml
addit
inhibit
varieti
retrovirus
synergi
demonstr
zidovudin
combin
didanosin
zalcitabin
lamivudin
nevirapin
delavirdin
saquinavir
indinavir
ritonavir
compound
first
drug
licens
treatment
hiv
infect
still
use
combin
drug
initi
therapi
patient
zidovudin
avail
capsul
syrup
intraven
formul
oral
bioavail
approxim
peak
plasma
level
achiev
approxim
h
treatment
zidovudin
penetr
cerebrospin
fluid
saliva
semen
breast
milk
cross
placenta
drug
predomin
metabol
liver
enzym
uridin
diphosphoglucuronosyltransferas
major
inact
metabolit
obdglucopyranuronosylthymidin
elimin
approxim
h
howev
extend
individu
alter
hepat
function
zidovudin
use
combin
antihiv
agent
administ
oral
mg
day
mg
tablet
twice
day
singl
import
usag
zidovudin
last
decad
peripartum
threepart
zidovudin
regimen
decreas
incid
transmiss
hiv
infect
pregnant
women
infant
predomin
advers
effect
zidovudin
myelosuppress
evidenc
neutropenia
anemia
occur
patient
respect
zidovudin
associ
skelet
cardiac
muscl
toxic
includ
polymyos
nausea
headach
malais
insomnia
fatigu
common
side
effect
chemistri
mechan
action
antivir
activ
didanosin
dideoxyinosin
purin
nucleosid
inhibitori
activ
didanosin
activ
intracellular
phosphoryl
first
convert
monophosph
nucleotidas
inosin
monophosph
phosphotransferas
subsequ
monophosph
adenylsuccin
synthetas
lyas
convert
diphosph
adenyl
kinas
subsequ
creatin
kinas
phosphoribosyl
pyrophosph
synthetas
triphosph
triphosph
metabolit
competit
inhibitor
hiv
revers
transcriptas
chain
termin
spectrum
activ
didanosin
enhanc
synerg
zidovudin
stavudin
well
proteas
inhibitor
didanosin
acid
labil
poor
solubl
buffer
tablet
result
bioavail
mg
oral
dose
achiev
peak
plasma
concentr
mg
ml
approxim
h
metabol
hypoxanthin
clear
primarili
kidney
didanosin
use
combin
antihiv
agent
part
haart
given
two
mg
tablet
buffer
tablet
twice
day
one
mg
capsul
delayedreleas
capsul
day
signific
advers
effect
associ
didanosin
therapi
develop
peripher
neuropathi
pancreat
lipoatrophi
lactic
acidosi
diabet
observ
patient
antiretrovir
regimen
contain
didanosin
chemistri
mechan
action
antivir
activ
zalcitabin
dideoxycytidin
pyrimidin
analogu
activ
cellular
enzym
triphosph
deriv
enzym
respons
activ
zalcitabin
cell
cycl
independ
therefor
offer
theoret
advantag
nondivid
cell
specif
dendrit
monocytemacrophag
cell
zalcitabin
inhibit
concentr
approxim
mmol
l
oral
bioavail
follow
zalcitabin
administr
peak
plasma
concentr
follow
oral
dose
mg
kg
rang
mmol
l
approxim
min
drug
clear
mainli
kidney
therefor
presenc
renal
insuffici
lead
prolong
plasma
zalcitabin
use
part
haart
regimen
infect
administ
oral
mg
day
one
mg
tablet
everi
h
peripher
neuropathi
major
toxic
associ
zalcitabin
administr
occur
approxim
individu
pancreat
occur
infrequ
thrombocytopenia
neutropenia
uncommon
respect
zalcitabinerel
side
effect
includ
nausea
vomit
headach
hepatotox
cardiomyopathi
chemistri
mechan
action
antivir
activ
stavudin
didehydro
deoxythymidin
thymidin
analogu
signific
activ
inhibitori
concentr
rang
mmol
l
mechan
action
similar
zidovudin
oral
bioavail
stavudin
peak
plasma
concentr
approxim
mg
ml
reach
within
h
dose
mg
kg
per
dose
stavudin
penetr
csf
breast
milk
excret
kidney
unchang
part
renal
tubular
secret
stavudin
use
hiv
infect
combin
antihiv
agent
stavudin
highli
potent
inhibitor
replic
vitro
howev
use
limit
delay
toxic
notabl
peripher
neuropathi
myopathi
caus
mitochondri
damag
administ
oral
mg
day
one
mg
capsul
everi
h
princip
advers
effect
stavudin
therapi
develop
peripher
neuropathi
develop
complic
relat
dose
durat
therapi
inhibit
mitochondri
dna
synthesi
propos
induc
deplet
cellular
mitochondri
dna
ultim
respons
delay
toxic
observ
use
stavudin
nucleosid
revers
transcriptas
inhibitor
nrti
neuropathi
tend
appear
month
therapi
resolv
slowli
medic
discontinu
side
effect
uncommon
fatal
nonfat
pancreat
occur
therapi
stavudin
part
combin
regimen
includ
didanosin
redistribut
accumul
bodi
fat
lipoatrophi
observ
patient
receiv
stavudin
part
antiretrovir
regimen
chemistri
mechan
action
antivir
activ
chemistri
mechan
action
lamivudin
describ
previous
section
lamivudin
therapeut
hepat
lamivudin
signific
activ
vitro
well
hbv
lamivudin
competit
inhibitor
viral
revers
transcriptas
lamivudin
use
combin
antihiv
agent
lamivudin
given
oral
mg
day
one
mg
tablet
twice
day
one
mg
tablet
day
also
formul
combin
zidovudin
zidovudin
abacavir
fixeddos
combin
tablet
lamivudin
extrem
favor
toxic
profil
may
larg
attribut
low
affin
lamivudin
human
dna
polymeras
lack
activ
lamivudin
metabolit
mitochondri
compart
cell
highest
dose
mg
kg
day
neutropenia
encount
low
frequenc
pediatr
studi
pancreat
peripher
neuropathi
report
chemistri
mechan
action
antivir
activ
abacavir
sulfat
cyclopropylamino
structur
analogu
purin
guanin
phosphoryl
pathway
abacavir
differ
nucleosid
analogu
first
step
convers
abacavir
activ
metabolit
carbovir
triphosph
phosphoryl
abacavir
monophosph
adenosin
phosphotransferas
step
follow
deamin
cytosol
enzym
form
carbovir
monophosph
undergo
two
subsequ
phosphoryl
diphosph
guanyl
kinas
triphosph
nucleosid
diphosph
kinas
enzym
carbovir
triphosph
compet
endogen
dgtp
incorpor
nucleic
acid
chain
incorpor
termin
dna
chain
elong
abacavir
exhibit
potent
vitro
antivir
activ
wildtyp
ic
mmol
l
activ
lower
activ
zidovudin
ic
mmol
l
howev
signific
differ
level
activ
abacavir
ic
mmol
l
azt
ic
mmol
l
clinic
isol
abacavir
well
absorb
oral
administr
bioavail
singl
multipl
dose
c
max
attain
mean
h
mean
halflif
h
howev
dose
mg
twice
daili
part
combin
regimen
level
intracellular
carbovir
triphosph
rang
fmol
per
cell
intracellular
carbovir
triphosph
measur
throughout
studi
period
highest
level
found
h
find
suggest
long
halflif
carbovir
triphosph
within
cell
main
rout
excret
renal
abacavir
use
combin
antihiv
agent
given
mg
tablet
twice
day
two
mg
tablet
day
fixeddos
combin
lamivudin
avail
mg
abacavir
plu
mg
lamivudin
abacavir
hypersensit
reaction
potenti
fatal
syndrom
occur
approxim
hivinfect
patient
expos
nucleosid
analogu
median
day
rang
day
system
manifest
includ
fever
rash
fatigu
gastrointestin
respiratori
symptom
rechalleng
abacavir
individu
presum
abacavir
hypersensit
reaction
avoid
due
report
fatal
reaction
caus
repeat
administr
abacavir
follow
hypersensit
reaction
presenc
hlab
associ
elev
odd
develop
abacavir
hypersensit
reaction
chemistri
mechan
action
antivir
activ
emtricitabin
hydroxymethyl
cytosin
fluorin
nucleosid
analogu
cytosin
emtricitabin
similar
mani
way
lamivudin
vitro
activ
similar
approxim
fourfold
tenfold
potent
lamivudin
ec
emtricitabin
rang
mmol
l
mg
ml
laboratori
clinic
isol
cell
cultur
ec
rang
mmol
l
cellular
enzym
involv
phosphoryl
emtricitabin
similar
lamivudin
activ
triphosph
competit
inhibit
revers
transcriptas
incorpor
viral
genom
caus
termin
dna
chain
elong
bioavail
capsul
oral
solut
respect
emtricitabin
rapidli
extens
absorb
follow
oral
administr
peak
plasma
concentr
occur
h
post
dose
mean
plasma
elimin
halflif
emtricitabin
singl
dose
h
hivinfect
patient
howev
multipl
dose
drug
dose
mg
daili
intracellular
halflif
approxim
h
high
intracellular
level
emtricitabin
triphosph
achiev
associ
better
suppress
plasma
hiv
rna
emtricitabin
inhibitor
human
enzym
emtricitabin
elimin
combin
glomerular
filtrat
activ
tubular
secret
emtricitabin
use
antihiv
agent
administ
oral
oncedaili
mg
capsul
emtricitabin
compon
truvada
fixeddos
combin
emtricitabin
tenofovir
disoproxil
fumar
atripla
fixeddos
combin
efavirenz
emtricitabin
tenofovir
disoproxil
fumar
common
advers
event
headach
diarrhea
nausea
rash
gener
mild
moder
sever
approxim
patient
discontinu
particip
clinic
trial
due
event
propyl
adenin
fumar
convert
tenofovir
acycl
nucleosid
phosphon
nucleotid
analogu
adenosin
tenofovir
disoproxil
fumar
requir
initi
diester
hydrolysi
convers
tenofovir
subsequ
phosphoryl
cellular
enzym
form
tenofovir
triphosph
tenofovir
triphosph
inhibit
activ
revers
transcriptas
compet
natur
substrat
deoxyadenosin
triphosph
incorpor
dna
dna
chain
termin
tenofovir
triphosph
weak
inhibitor
mammalian
dna
polymeras
b
mitochondri
dna
polymeras
g
tenofovir
antivir
activ
vitro
ic
valu
rang
mmol
l
ic
valu
tenofovir
rang
mmol
l
oral
bioavail
tenofovir
fast
patient
approxim
follow
oral
administr
singl
dose
mg
infect
patient
maximum
serum
concentr
achiev
ae
h
c
max
auc
valu
ae
ng
ml
ae
ng
h
ml
respect
oral
bioavail
increas
tenofovir
administ
highfat
meal
fat
vitro
studi
indic
neither
tenofovir
disoproxil
tenofovir
substrat
enzym
tenofovir
primarili
excret
kidney
combin
glomerular
filtrat
activ
tubular
secret
pharmacokinet
tenofovir
alter
patient
renal
impair
tenofovir
use
combin
antihiv
agent
treatment
infect
administ
oral
daili
mg
tablet
common
advers
reaction
seen
doubleblind
compar
control
studi
mild
moder
gastrointestin
event
dizzi
howev
follow
advers
event
identifi
postapprov
use
tenofovir
allerg
reaction
hypophosphatemia
lactic
acidosi
dyspnea
abdomin
pain
increas
amylas
pancreat
increas
liver
enzym
hepat
renal
insuffici
renal
failur
fanconi
syndrom
proxim
tubulopathi
proteinuria
increas
creatinin
acut
tubular
necrosi
nephrogen
diabet
insipidu
resist
nucleosidenucleotid
analogu
nucleosid
analogueassoci
mutat
nam
develop
least
three
pathway
accumul
zidovudin
thymidin
analogu
resist
mutat
tam
eg
l
n
w
select
key
mutat
follow
mutat
v
l
refer
complex
insert
complex
consist
mutat
codon
typic
ser
follow
insert
two
amino
acid
eg
serser
serarg
sergli
gener
accompani
nam
clinic
isol
two
tam
pathway
observ
l
w
n
combin
preval
cytidin
analogu
select
mutat
lamivudin
emtricitabin
seen
tenofovir
select
pressur
resist
pattern
earlier
nucleosid
analogu
combin
zidovudin
stavudin
lamivudin
resist
profil
seen
earlier
nucleosid
analogu
combin
well
character
thymidinebas
nrti
lamivudinezidovudin
stavudinelamivudin
mutat
emerg
rapidli
wherea
tam
slower
aris
use
emtricitabin
place
lamivudin
would
presum
yield
similar
result
although
clinic
data
limit
mutat
shown
increas
zidovudin
suscept
absenc
presenc
zidovudin
resist
mutat
without
regard
tam
combin
present
mutat
may
increas
sensit
tenofovir
commonli
observ
mutat
zidovudinedidanosin
stavudinedidanosin
tam
tam
multinucleosid
resist
mnr
mutat
insert
preval
didanosinecontain
regimen
lamivudinecontain
regimen
resist
pattern
new
nucleosidenucleotid
analogu
combin
abacavirlamivudin
backbon
common
mutat
select
follow
mutat
treatment
failur
major
mutat
select
vitro
tenofovir
alon
combin
abacavir
lamivudin
abacavir
appear
favor
triplenucleosidenucleotid
regimen
tenofovirlamivudinedidanosin
tenofovirlamivudineabacavir
lack
thymidin
analogu
earli
treatment
failur
associ
high
frequenc
addit
patient
also
harbor
chemistri
mechan
action
antivir
activ
nevirapin
e
revers
transcriptas
inhibitor
howev
mechan
action
differ
nucleosid
analogu
bind
hydrophob
pocket
adjac
activ
site
revers
transcriptas
caus
conform
chang
affect
replic
nevirapin
bioavail
approxim
peak
serum
concentr
mg
ml
achiev
approxim
h
mg
oral
dose
nevirapin
metabol
liver
microsom
hydroxymethylnevirapin
nevirapin
use
combin
antihiv
agent
administ
oral
mg
day
first
day
one
mg
tablet
per
day
mg
day
two
daili
mg
tablet
singledos
nevirapin
use
wide
resourcelimit
set
prevent
mothertochild
transmiss
hiv
infect
common
advers
effect
includ
develop
nonprurit
rash
mani
patient
receiv
mg
day
addit
fever
myalgia
headach
nausea
vomit
fatigu
diarrhea
also
associ
administr
drug
chang
two
set
amino
acid
residu
revers
transcriptas
gene
confer
resist
nevirapin
nevirapin
monotherapi
associ
resist
frequent
appear
codon
delavirdin
use
combin
antihiv
agent
administ
mg
day
two
mg
tablet
three
time
day
delavirdin
administr
associ
maculopapular
rash
side
effect
less
common
delavirdin
resist
gener
rapidli
vitro
vivo
codon
chang
identifi
result
increas
suscept
mmol
l
delavirdin
resist
confer
mutat
codon
seen
nonnucleosid
analogu
chemistri
mechan
action
antivir
activ
efavirenz
cyclopropylethynyl
trifluoromethyl
nonnrti
administ
daili
activ
mediat
predomin
noncompetit
inhibit
revers
transcriptas
revers
transcriptas
human
cellular
dna
polymeras
b
g
inhibit
efavirenz
inhibitori
concentr
efavirenz
approxim
nmol
l
efavirenz
use
combin
antiretrovir
agent
treatment
infect
combin
therapi
result
greater
decreas
rna
level
common
advers
event
skin
rash
associ
blister
moist
desquam
ulcer
addit
delus
inappropri
behavior
report
patient
per
resist
efavirenz
caus
mutat
revers
transcriptas
gene
nonnucleosid
analogu
appear
rapidli
chemistri
mechan
action
antivir
activ
etravirin
amino
oxi
nonnrti
activ
etravirin
activ
nnrtiresist
virus
nanomolar
rang
andri
et
al
activ
mediat
predomin
noncompetit
inhibit
revers
transcriptas
etravirin
inhibit
human
dna
polymeras
b
g
follow
oral
administr
etravirin
absorb
max
h
absolut
bioavailabilti
etravirin
unknown
administr
etravirin
fast
condit
decreas
auc
etravirin
bound
plasma
protein
predominantli
albumin
howev
antivir
activ
affect
presenc
human
serum
andri
et
al
etravirin
metabol
liver
elimin
approxim
h
etravirin
substrat
cytochrom
isoenzym
drug
induc
inhibit
cytochrom
isoenzym
may
alter
therapeut
effect
side
effect
etravirin
efavirenz
use
combin
antiretrovir
agent
treatment
infect
recommend
dose
mg
twice
daili
follow
meal
common
advers
event
moder
sever
intens
least
skin
rash
peripher
neuropathi
lazzarin
et
al
resist
etravirin
caus
mutat
revers
transcriptas
gene
nnrti
howev
unlik
nnrti
concurr
presenc
three
mutat
requir
substanti
reduc
suscept
etravirin
lazzarin
et
al
oral
administr
maximum
plasma
concentr
rilpivirin
gener
achiev
within
h
absolut
bioavail
unknown
rilpivirin
approxim
bound
plasma
protein
vitro
primarili
albumin
rilpivirin
primarili
metabol
cytochrom
drug
induc
inhibit
may
thu
affect
clearanc
rilpivirin
elimin
rilpivirin
approxim
h
rilpivirin
use
combin
antiretrovir
agent
treatment
infect
recommend
dose
mg
oral
day
meal
rilpivirin
effect
efavirenz
hiv
patient
howev
develop
resist
virolog
failur
occur
frequent
rilpivirin
efavirenz
cohen
et
al
molina
et
al
advers
effect
rilpivirin
includ
depress
insomnia
headach
rash
fewer
patient
discontinu
rilpivirin
contain
therapi
due
advers
effect
efavirenz
contiainign
therapi
vs
resist
rilpivirin
caus
mutat
revers
transcriptas
gene
nnrti
crossresist
efavirenz
etravirin
andor
nevirapin
like
virolog
failur
develop
rilpivirin
resist
chemistri
mechan
action
antivir
activ
raltegravir
structur
analogu
class
compound
distinct
diketo
acid
moieti
novel
integras
inhibitor
potent
vitro
activ
ic
nmol
l
presenc
human
serum
activ
wide
rang
wildtyp
multidrugresist
clinic
isol
potent
activ
virus
use
andor
coreceptor
entri
raltegravir
absorb
rapidli
median
max
valu
fast
state
h
plasma
concentr
decreas
c
max
biphas
manner
halflif
approxim
h
initi
phase
appar
halflif
approxim
h
termin
b
phase
pharmacokinet
data
raltegravir
support
twice
daili
administr
metabol
hepat
glucuronid
effect
approxim
raltegravir
dose
excret
unchang
urin
raltegravir
receiv
prioriti
approv
fda
octob
treatment
infect
combin
antiretrovir
agent
treatmentexperienc
patient
evid
replic
despit
ongo
antiretrovir
therapi
dosag
raltegravir
mg
administ
oral
twice
daili
without
food
side
effect
mostli
mild
moder
seen
similar
frequenc
raltegravir
placebo
arm
rate
seriou
advers
event
less
across
arm
lipid
abnorm
report
far
raltegravir
sever
mutat
identifi
patient
fail
raltegravir
contain
regimen
includ
rh
da
silva
et
al
chemistri
mechan
action
antivir
activ
elvitegravir
first
gener
integras
inhibitor
potent
vitro
activ
activ
wide
rang
wildtyp
multidrugresist
clinic
isol
potent
activ
virus
elvitegravir
rapidli
absorb
achiev
maximum
concentr
h
elvitegravir
metabol
halflif
significantli
increas
coadministr
pharmacoenhanc
like
ritonavir
inhibit
metabol
pathway
twice
daili
mg
dose
elvitegravir
alon
steadyst
condit
achiev
auc
mg
h
ml
cv
c
mg
ml
cv
howev
mg
elvitegravir
boost
mg
ritonavir
auc
c
increas
mg
h
ml
cv
c
mg
ml
cv
respect
mathia
et
al
elvitegravir
approv
fda
august
part
fixeddos
daili
tablet
contain
tenofovir
emtricitabin
cytochrom
isoenzym
inhibitor
cobicistat
treatment
infect
sax
et
al
advers
effect
elvitegravir
appear
may
includ
diarrhea
rash
laboratori
abnorm
includ
elev
hepat
transaminas
resist
elvitegravir
associ
select
resist
mutat
vitro
vivo
studi
show
emerg
number
integras
mutat
includ
kobayashi
et
al
mg
daili
monotherapi
dolutegravir
day
infect
adult
result
mean
log
reduct
rna
min
et
al
dolutegravir
absorb
rapidli
dosedepend
kinet
low
appar
clearanc
oral
termin
h
support
daili
dose
without
need
boost
agent
min
et
al
mg
dose
dolutegravir
steadyst
condit
achiev
geometr
mean
c
max
mg
ml
cv
auc
mg
h
ml
cv
h
cv
c
mg
ml
cv
metabol
primarili
via
minor
contribut
substrat
pglycoprotein
induc
inhibitor
min
et
al
approxim
dolutegravir
dose
recov
unchang
fece
urin
respect
castellino
et
al
dolutegravir
receiv
prioriti
approv
fda
august
treatment
infect
combin
antiretrovir
agent
adult
children
age
year
older
weigh
least
kg
dosag
dolutegravir
mg
administ
oral
daili
without
food
dosag
dolutegravir
mg
twice
daili
coadminist
follow
potent
induc
efavirenz
fosamprenavirritonavir
tipranavirritonavir
rifampin
dolutegravir
gener
well
toler
effect
clinic
trial
advers
effect
least
moder
intens
grade
occur
particip
dolutegravir
insomnia
headach
walmsley
et
al
treatmentna
particip
small
mean
elev
serum
creatinin
rang
mg
dl
observ
dolutegravir
higher
barrier
resist
raltegravir
elvitegravir
vitro
well
clinic
data
indic
primari
mutat
codon
mutant
remain
suscept
dolutegravir
wherea
mutat
codon
presenc
secondari
mutat
lead
decreas
dolutegravir
efficaci
hare
et
al
proteas
inhibitor
use
combin
antihiv
agent
treatment
hiv
infect
potent
compon
haart
regimen
proteas
inhibitor
use
combin
ritonavir
boost
proteas
inhibitor
concept
boost
involv
pharmacokinet
drug
interact
current
avail
proteas
inhibitor
metabol
liver
cytochrom
enzym
system
ritonavir
power
enzym
inhibitor
proteas
inhibitor
class
combin
ritonavir
allow
boost
proteas
inhibitor
maintain
prolong
blood
level
allow
decreas
dosag
reduc
three
time
day
schedul
twice
daili
even
daili
regimen
longterm
haart
contain
proteas
inhibitor
strongli
associ
syndrom
character
dyslipidemia
peripher
lipodystrophi
insulin
resist
saquinavir
inhibit
concentr
nmol
l
synergist
nucleosid
analogu
well
select
proteas
inhibitor
oral
bioavail
approxim
extens
hepat
metabol
peak
plasma
concentr
mg
ml
obtain
follow
mg
dose
clinic
efficaci
saquinavir
limit
poor
oral
bioavail
improv
formul
softgel
capsul
enhanc
efficaci
saquinavir
boost
mg
twice
day
ritonavir
improv
bioavailabilti
efficaci
even
saquinavirresist
hiv
strain
advers
effect
minim
doselimit
toxic
abdomin
discomfort
includ
diarrhea
nausea
report
infrequ
mutat
codon
site
proteas
gene
result
approxim
decreas
suscept
saquinavir
indinavir
rapidli
absorb
bioavail
achiev
peak
plasma
concentr
mmol
l
mg
oral
dose
although
indinavir
well
toler
commonli
encount
advers
effect
includ
indirect
hyperbilirubinemia
nephrolithiasi
indinavir
resist
develop
rapidli
monotherapi
occur
multipl
site
extent
resist
directli
relat
number
codon
chang
hiv
proteas
gene
codon
common
mutat
indinavirresist
hiv
isol
chemistri
mechan
action
antivir
activ
ritonavir
lyl
phenylmethyl
thiazolylmethylest
hiv
proteas
inhibitor
activ
vitro
laboratori
strain
mmol
l
synergist
administ
nucleosid
analogu
oral
bioavail
approxim
peak
plasma
level
approxim
mmol
l
mg
administ
everi
h
plasma
halflif
approxim
h
advers
effect
includ
nausea
diarrhea
headach
occur
low
frequenc
ritonavir
crossresist
indinavir
mutat
codon
common
chemistri
mechan
action
antivir
activ
nelfinavir
hydroxyphenyl
pentyl
tertbutylcarboxamid
methanesulfon
acid
salt
anoth
peptidomimet
hiv
proteas
inhibitor
inhibitori
concentr
rang
nmol
l
activ
nelfinavir
oral
bioavail
approxim
achiev
peak
plasma
concentr
mg
follow
mg
dose
everi
h
drug
metabol
hepat
microsom
nelfinavir
well
toler
mild
gastrointestin
complic
report
crossresist
proteas
inhibitor
particularli
saquinavir
indinavir
ritonavir
common
frequent
demonstr
site
mutat
codon
chemistri
mechan
action
antivir
activ
amprenavir
hydroxyethylamin
sulfonamid
peptidomimetr
structur
identifi
n
isobutylbenzenesulfonamido
activ
concentr
nmol
l
oral
bioavail
peak
plasma
concentr
mg
ml
achiev
dosag
mg
plasma
halflif
h
csf
concentr
signific
amprenavir
metabol
liver
cytochrom
enzym
system
common
advers
event
gastrointestin
event
nausea
vomit
diarrhea
abdomin
paindiscomfort
mild
moder
sever
also
skin
rash
occur
patient
amprenavir
genotyp
analysi
isol
treatmentna
patient
fail
amprenavircontain
regimen
show
mutat
proteas
gene
result
amino
acid
substitut
primarili
posit
well
mutat
gag
gagpol
polyprotein
cleavag
site
sulfonyl
isobutyl
amino
phosphonooxi
propylcarbam
monocalcium
salt
inhibitor
human
hiv
proteas
fosamprenavir
rapidli
hydrolyz
amprenavir
enzym
gut
epithelium
administr
singl
dose
fosamprenavir
patient
peak
concentr
occur
h
median
h
amprenavir
metabol
liver
cytochrom
enzym
system
plasma
elimin
halflif
amprenavir
approxim
h
side
effect
profil
similar
amprenavir
fosamprenavir
select
amprenavirassoci
mutat
treatment
failur
though
much
lower
incid
chemistri
mechan
action
antivir
activ
lopinavir
n
acetylamino
benzylpentyl
butanamin
inhibitor
hiv
proteas
prevent
cleavag
gagpol
polyprotein
result
product
immatur
noninfecti
viral
particl
coformul
ritonavir
ratio
kaletra
presenc
human
serum
mean
ec
valu
lopinavir
laboratori
strain
rang
nmol
l
mg
ml
activ
strain
lopinavir
peak
plasma
concentr
occur
approxim
h
administr
lopinavir
metabol
ritonavir
inhibit
metabol
lopinavir
therebi
increas
plasma
level
lopinavir
common
advers
event
nausea
diarrhea
increas
cholesterol
triglycerid
lipodystrophi
virolog
respons
lopinavirritonavir
shown
affect
presenc
three
follow
amino
acid
substitut
proteas
baselin
atazanavir
exhibit
activ
ec
absenc
human
serum
nmol
l
varieti
laboratori
clinic
isol
vitro
atazanavir
rapidli
absorb
max
approxim
h
atazanavir
metabol
liver
cytochrom
enzym
system
mean
elimin
halflif
atazanavir
healthi
volunt
hivinfect
adult
patient
approxim
h
common
advers
event
patient
asymptomat
elev
indirect
unconjug
bilirubin
relat
inhibit
udpglucuronosyl
transferas
ugt
hyperbilirubinemia
revers
upon
discontinu
atazanavir
atazanavir
may
caus
abnorm
electrocardiogram
find
increas
serum
glucos
lipodystrophi
patient
isol
decreas
suscept
atazanavir
select
vitro
obtain
patient
treat
atazanavir
atazanavirritonavir
mutat
associ
resist
atazanavir
atazanavirresist
clinic
isol
treatmentna
harbor
mutat
averag
week
atazanavir
therapi
often
combin
mutat
howev
viral
isol
mutat
phenotyp
resist
atazanavir
show
vitro
suscept
proteas
inhibitor
amprenavir
indinavir
lopinavir
nelfinavir
ritonavir
saquinavir
propyl
phenyl
trifluoromethyl
nonpeptid
hiv
proteas
inhibitor
belong
class
sulfonamid
tipranavir
inhibit
replic
laboratori
strain
clinic
isol
vitro
ec
rang
mmol
l
ng
ml
effect
mean
elimin
halflif
tipranavirritonavir
healthi
volunt
hivinfect
adult
patient
approxim
h
respect
steadi
state
follow
dose
mg
twice
daili
light
meal
tipranavir
predominantli
metabol
cyp
enzym
system
tipranavir
coadminist
mg
ritonavir
use
combin
antihiv
agent
treatment
infect
adult
highli
treatmentexperienc
evid
viral
replic
strain
resist
multipl
proteas
inhibitor
respons
rate
reduc
five
proteas
inhibitorassoci
mutat
present
baselin
patient
given
concomit
enfuvirtid
tipranavirritonavir
advers
event
includ
rash
increas
cholesterol
increas
triglycerid
lipodystrophi
hepat
report
fatal
nonfat
intracrani
hemorrhag
use
tipranavirritonavir
tipranavirritonavir
use
caution
patient
may
risk
increas
bleed
trauma
surgeri
medic
condit
receiv
medic
known
increas
risk
bleed
antiplatelet
agent
anticoagul
isol
resist
tipranavir
select
vitro
month
contain
proteas
mutat
develop
follow
order
clinic
trial
tipranavir
less
fourfold
decreas
suscept
isol
resist
amprenavir
atazanavir
indinavir
lopinavir
nelfinavir
ritonavir
saquinavir
tipranavirresist
virus
select
vitro
decreas
suscept
proteas
inhibitor
amprenavir
atazanavir
indinavir
lopinavir
nelfinavir
ritonavir
remain
sensit
saquinavir
inhibitor
hiv
proteas
darunavir
exhibit
activ
laboratori
strain
clinic
isol
laboratori
strain
median
ec
valu
rang
nmol
l
ng
ml
darunavir
coadminist
mg
ritonavir
twice
daili
absorb
follow
oral
administr
max
approxim
h
absolut
oral
bioavail
singl
mg
dose
darunavir
alon
coadministr
mg
ritonavir
twice
daili
respect
darunavir
primarili
metabol
ritonavir
inhibit
therebi
increas
plasma
concentr
darunavir
given
combin
darunavir
coadminist
mg
ritonavir
antihiv
agent
indic
treatment
hiv
infect
antiretrovir
treatmentexperienc
adult
patient
strain
resist
one
proteas
inhibitor
common
treatmentemerg
advers
event
report
de
novo
subject
regardless
causal
frequenc
diarrhea
nausea
headach
nasopharyng
side
effect
increas
triglycerid
increas
cholesterol
lipodystrophi
increas
glucos
increas
liver
enzym
level
darunavirresist
viru
deriv
cell
cultur
wildtyp
hiv
decreas
suscept
darunavir
harbor
three
six
follow
amino
acid
substitut
proteas
phase
iib
trial
amino
acid
substitut
develop
darunavirritonavir
mg
twice
day
greater
virolog
failur
isol
substitut
amino
acid
posit
develop
greater
virolog
failur
isol
substitut
develop
darunavirritonavir
virolog
failur
isol
occur
amino
acid
posit
simplif
haart
regimen
high
prioriti
mani
year
number
effect
drug
increas
number
possibl
effect
regimen
trend
toward
fixeddos
combin
oncedaili
dosag
form
mani
antiretrovir
drug
provid
welcom
relief
patient
follow
multiclass
fix
dose
combin
agent
approv
fda
atripla
efavirenz
emtricitabin
tenofovir
complera
emtricitabin
rilpivirin
tenofovir
stribild
elvitegravir
cobicistat
emtricitabin
tenofovir
medic
burden
simplifi
consequ
improv
adher
therapi
experi
better
control
hiv
thu
reduc
morbid
new
drug
discoveri
strategi
attempt
circumv
current
drug
resist
problem
focus
either
novel
target
new
compound
capabl
suppress
hiv
strain
resist
current
inhibitor
sever
nucleosid
analogu
preclin
clinic
studi
notabl
novel
substitut
thymidin
analogu
potent
antivir
activ
less
cytotox
exampl
recent
discov
ethynylthymidin
structur
relat
stavudin
potent
inhibitor
replic
much
less
inhibitori
mitochondri
dna
synthesi
cell
growth
cell
cultur
progenitor
stavudin
triphosph
metabolit
accumul
cell
much
longer
stavudin
exert
persist
antivir
activ
even
remov
drug
cultur
paintsil
et
al
also
uniqu
resist
profil
compar
thymidin
analogu
maintain
activ
multidrug
resist
hiv
strain
increas
number
compound
discov
antihiv
agent
target
virtual
step
replic
cycl
viru
novel
target
develop
anticip
new
effect
treatment
viral
infect
avail
advent
modern
improv
technolog
base
molecular
biolog
combinatori
chemistri
computeraid
design
compound
greater
specif
target
viral
life
cycl
